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ABSTRACT 
II 
ABSTRACT 
Backgroun d :  Oiabete mel l itu (OM) is one of the mo t common exocrine di  orders 
affecting more than 6 °0 r the world's population. The inc idence and prevalence of this 
chroni di ea e are on the ri e in many parts of the world inc luding the Middle East . OM 
i cau d by defective in ul in production, relea e and/or function. The causes and nature 
of  abnonnal in u l in metaboli m i less than c lear. While defecti e insulin secretion is 
ob erved in type 1 diabetes, insulin resistance is predominant in type 2 diabetes, which 
affe t more than 94°0 of the diabetic patient . 
Materials and Methods:  Rats between the age of two and three months were divided in to 
n ine group each consisting of 12 rats: Goto Kakizaki (GK) nornlal ,  GK treated with visfatin, 
GK treated with adiponectin, Wi star diabetic rats treated with visfatin, Wistar diabetic rats 
treated with adiponectin, onnal Wistar treated with visfatin, Nonnal Wistar rats treated 
with adiponectin untreated diabetic Wistar rats, and nomlal untreated Wi tar rats. 
Oiabete in Wistar rats was induced by a single intraperitoneal injection of streptozotocin 
(60 mg kg'I ) .  One week from induction of diabetes, selected groups received intraperitoneal 
injection of ( 1 0  ng/kg body weight) either adiponectin or visfatin for 1 4  weeks. Al l animals 
from all groups were sacri ficed after 1 4  weeks of treatment for blood plasma biochemistry 
analysis. The pancreas was rapidly removed and representati e fragments were taken to be 
u ed for i mmunohistochemical,  immunofluorescence, and electron microscopy studies. 
Resul ts :  Adiponectin and visfatin improved gluco e tolerance in Wistar as wel l as GK 
rats. In addition, the number and qual i ty of  pancreatic beta cel ls improved after treatment 
with adiponectin and visfatin leading to increase in the plasma level of insulin.  Liver and 
kidney parameters inc luding lactic acid dehydrogenase, alkaline phosphatase, blood urea 
n itrogen decreased significantly after treatment with either adiponectin or visfatin. 
Conc lusion : Adiponectin and visfatin ameliorate several metabolic parameters in animal 
models of type 1 and type 2 diabetes, resulting in improved g lycemic control .  
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LITERATURE REVIEW 
I .  D ia betes 
1 .  L .  Defin it ion 
Diabete mel l itus ( DM) i a disea e defined by WHO as  a metabolic disorder of multiple 
etiology, characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and 
prot in metabol ism re ult ing from defect in insulin secret ion, insulin action or both. The effects 
of diabete mel l itus include short and long-term damage, dysfunction and fai lure of various 
organ ( 1 ) . 
The effect of  the di ea e may be acute or chronic, in olving many organs, including the 
eye, the kidney, peripheral nerves and large artelies. Primary diabetes mel l itus is traditional ly 
divided into either type 1 ( insul in dependent IDDM) or type 2 (non-insul in dependent, N I DDM) .  
The c las i fication is  important because of the di fferent genetic backgrounds, c l inical 
pre entations, metabolic effects treatment and consequences of the two types. Diabetes may also 
be secondary to other disorder (2 ) .  
1 . 2 .  C l a ssificat ion 
Usual ly, diabete was c lassified according to  the patient's age at onset of symptoms. In  
1 979, the  IH diabete data group proposed a plan to  divide diabetes into two main types (3) :  
1 .  Insul in dependent and, 
2. on - insul in dependent 
B ut this "therapeutic c lassification" proved unacceptable as more infonnation on pathogenesis  
and etiology of  diabetes mel l itus accumulate in 1 997.  
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The lntemational Committee of Diabetologi t sugge ted that several changes in the 
c ia i ficati 11 o r  diabete that ha been endorsed by the American Diabetes As ociation and the 
World Health Organization can include the fol lowing (3) :  
1 .  The term - insu l in - independent diabetes mel l i tus and on - insulin - dependent diabetes 
mel l i tu a' their acronym IDDM and IDDM to be eliminated. 
2. The tenn type 1 diabetes and type 2 diabetes are retained with Arabic rather than roman 
numeral . 
1 .2 .  a. Type 1 d iabetes mel l i tus  
Type 1 i s  associated with ketosis in  the untreated state. Approximately 9 0 0 of diabetics 
from orth America and 20 010 of diabetics from the Scandinavian countries have type 1 diabetes 
(3 ) .  It i mo t common in young individuals but may occur in non-obese adults. It is a metabol ic 
disorder in which c irculating insul in is nearly absent. When plasma glucose is elevated the 
pancreatic B cel l s  fai l s  to react and hyperglycemia develops. There are three main target tissues 
of insu l in  ( l i ver, muscle and fat) .  In the absence of insulin, glucose uptake by these tissues is 
impaired. In  addition, alterations in fat metabolism lead to the production and accumulation of 
ketone bodies (3A) .  
Type 1 diabetes i s  believed to  be  a result of an exposure of a genetical ly predisposed 
person to infection or toxin or environmental insult resulting in the development of antibodies 
that destroy pancreati c  B cel ls .  Infectious and environmental factors implicated in the etiology of 
type 1 diabetes include v i ruses (mumps, rubel l a, coxsackievirus, B4), toxic chemical agents such 
as vacor (a n itrophenylurea rat poison) and other destructive cytotoxins such as hydrogen 
cyanide from spoi led tapioca or cassava root (3) .  
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1 .2. b.  ype 2 diabete meL l i tu  
Typ 2 diabete , formerly c la  ified as  non-insulin-dependent diabetes ( IDDM) occur 
in indi" idual with a relati" , rather than ab olute insulin defic iency and may be accompanied by 
in ul in re i tan e. It accounts for more than 90 % of diabetes cases in the United States. The 
patient are u ual ly  adult , age range to 40 years old and above, with some degree of obesity. 
The do not nonnal ly  require insulin to survive, alth ugh their in ulin secretory capacity 
tend to depr c iate, and many needs insulin treatment to achieve optimal glucose control .  Ketosis 
rarely  occur , but if pre ent, it is usual ly an outcome of associated stress, trauma or infection. 
Although th etiology of the primary defect in type 2 diabetes is unclear and presumabl y  multi 
factorial ,  i t  is well known that tissue insensitivity to insulin has been noted in most type 2 
patient regardle  s of weight. Subgroups of type 2 diabetes have recently been identified: 
i -Obese type 2 diabetes: 
Patients with this type of  diabetes mostly  present with insulin resistance. Several 
inve tigators consider that this type of diabetes may represent only one facet of a metabol ic 
syndrome. They noted that the well estab l ished association of hyperglycemia, hyperinsul inemia 
dysl ipidemia and hypertension, leads to coronary artery disease and stroke. It  may result from a 
genetic defect producing insu l in  resistance, especial ly when obesity aggravates the degree of 
insulin resistance (3 ) .  
The prevalence of  obesity is more than 30% of  Chinese and Japanese patients with type 
2 diabetes. It is present in 60 - 70 % of North America whi le Europeans or African with type 2 
diabetes approach 1 00 % of type 2 patients. Among Pima Indians or Pacific Islanders from 
auru or Samoa, patients with type 2 diabetes have insensitivity to endogenous insul in, which is 
correlated with the presence of  mainly abdominal distlibution of fat, producing an abnonnal high 
waist to hip ratio (3 ) .  
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2- on obe e type 2 diabetes 
Poor in ul in release by the pancreatic B cel l seems to be the main defect in non-obese 
type 2 diabet ic patIents but some insul in  resistance at the post receptor Ie el can also be 
detected. However, the degree of insul in  re istance does not appear to be c l inically appl icable to 
the treatment of mo t non-obese type 2 patients, who general ly  respond to appropriate 
therapeutic supplements of insulin i.n the absence of rare associated conditions such as 
l ipoatrophy of acanthu es nigricans (3 ) .  At present, type 2 diabetes is considered to be of an 
idiopathic origin.  On the other hand, with developments in biotechnology, a variety of etiologic 
genetic abnorn1al itie has been documented within a heterogeneous group, mainly those 
pre enting with c l inical and laboratory manifestations similar to those in the non-obese type 2 
ubgroup(3) .  
When the genetic defect has been defmed, these patients were reclassified within this group as 
"other specific types" (3 ) .  
1 .2 .  c .  Gestational diabetes 
Ge tational diabetes is defined as carbohydrate intolerance of varying degrees of severity with 
onset or first recognition during pregnancy. It  occurs in 2% to 5% of all pregnancies ( 5 ) .  
Although the risks associated with gestat ional diabetes are wel l  recognized, i t  remains uncertain 
whether screening and treatment to reduce maternal g lucose levels reduce these risks. 
5 
1 .3 .  y m pto m s  a n d  d i agnosi  
Recent tudie indicate that early detection of diabetes symptoms and treatment can 
decrea e the chance of developing the compl ications of diabetes. The symptom of type 1 and 
type 2 diabete \'ary in and depends on the sevelity and type of the disease. Diabetes is 
a ociated with frequent urination, lillU ual thirst, extreme hunger, unusual weight loss and 
extreme fatigue and irritabi l ity. Long standing diabetic may have some or all  of the fol lowing 
ymptom depending on the degree of morbidity: blurred vi ion, cutslbruises that are slow to 
heaL t ingl ing/nw11bness in the hands/feet and recurring skin, gum, or bladder infections (4) .  
1 .4.  C o mpl ica ti on  of d i a betes m e l l i tus  
Compl ications of D M  are mainly either acute or  chronic :  
1 04 .  a.  Acu te compl ications of DM : 
The most important acute complications of DM are metabol ic :  diabetic ketoacidosis, 
hypoglycaemia, lactic ac idosis and non-ketotic hyperosmolar coma. Other acute complications 
include acute infections and acute neuropathy (6).  Acute infections may be the presenting 
complaint in type 2 DM. They may include: candidal infections, carbuncles, boi ls  and other 
taphylococcal skin infections osteomyelitis, urinary infections pneumonia, tuberculosis and 
other systemic bacterial infections in the diagnosed diabetic, finger pulp infections caused by 
non-steri l e  fmger pricks (6). Acute motor or sensory neuropathy may be seen in various guises 
during or after a period of poor metabol ic contro l .  These neuropathies commonly present in the 
foml of amyotrophic pain and skin tenderness with weakness and wasting of the upper thigh 
muscles. These complications may resolve with improved glycemic control (often with insul in) 
(6) .  
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1 .... . h.  h ronic  compJ icat ions of  D M  
1 0  t o f  the chronic compl ications of diabetes result from disease of either the larae blood o 
,e el (macr augi pathy) or the mall blood ves els (microangiopathy). Macroangiopathy i 
re pon ible for a high prevalence of  coronary, peripheral and cerebral artery disease in diabetics. 
H yperten ion oexi t with DM in about 50% of patients. Accelerated atherosclerosis occurs at a 
young age and run an aggressive cour e in DM, especial ly in women. It accounts for most 
deaths, particularly in type 2 DM.  Microangiopathy is a general ized microvascular (capi l lary) 
di order that i s  spec i fic to D M  and c l inical ly  most apparent in the eyes, kidneys and nerves (6) .  
1 .5.  T rea t m e n t  a n d  m a n agem e n t  of d i a betes mel l i tus  
Treatment of a l l  types of  DM is intended to  lower b lood glucose level at most possible nonnal 
average by admini  tering insul in or oral hypoglycemic drugs and/or dietary modification. In type 
1 DM, patients are given insu l in and go on dietary therapy. This al lows the body to use up 
glucose as an energy source. In type 2 DM, dietary modification is the main factor of treatment. 
In addition, l ife style modification is also recommended. But physical effort should be 
recommended by the patient ' s  treating doctor. The patient is usual ly recommend to practice l ight 
exercise such as walking and swimming to use up a part the body' s glucose (7) .  
Patient and fami ly  education, diet and nutritional recommendations, physical exercise treatment 
of obesity, oral ant i-hyperglycemic agents, insulin and management of associated conditions and 
complications forms the comerstone of the management of DM and vary from country to 
country (5) .  
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1 .6 .  E p id e m io logy of d i a betes mel l i tus  i n  t h e  U A E  
The prevalence o f  impaired gluco e tolerance ( lOT) and diabetes b a  ed o n  the World 
Health Orgrulization and the E Ministry of Health ( 5 )  between the year 1 998-2000 on 6,609 
male and female (2, 363 AE nationals and 4,246 expatriates) individuals above the age of 2 1  
years were a fol low : 
T tal OM 1 9 .60 0, lOT 1 5 .20 0 
AE national OM 240 0, lOT 1 7 .90 0 
Expatriate OM 1 7 .40 0, lOT 1 3 .4% 
In the UAE, prevention of type 2 D M  epidemic in adolescents is encouraged by reducing 
chi ldhood obesity. which remains a major publ ic health challenge. The emergence of type 2 OM 
in chi ldren is  c losely l inked with obesity. Recent study shows that the presence of type 2 DM in 
the AE pediatric population has a maj or publ ic  health impl icat ion (8) .  The high prevalence of 
type 2 D M  in the UAE adult  population and obesity in chi ldren (8)  pose a sever health risk in the 
population. 
A more recent result on the epidemiology of diabetes reported increases in the prevalence 
of OM (34) .  Diabetes takes i ts flllancial tol l  on the UAB. According to the Ministry of Health, 
heart disease related to diabetes wa the first ki l ler in the UAB l ast year, comprising 3 1  per cent. 
Moreover, the UAE spends between US$ 1 00 and US$200 mi l l ion ( Oh367 to Oh734 mi l l ion) 
annual ly  on treating diabetes (9). Research and statistics report on diabetes across the UAE 
suggest that the disease wi l l  cost an estimated Dh 1 0 b i l l ion by the year 2020 if  the condition is 
not treated ( 1 0) .  
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I I . Obes ity 
n . t .  Defi n it ion a n d  c a u  es 
Body weight i mo t commonly asses ed by body mass index (BMI)  which i calculated 
by di\ iding an indi\ idual ' weight measured in kilograms by their height in meters squared. 
Therefore ovel\veight i defined as a B M I  of 25 .0-29.9 kg/m2 and obese is a BMI 2:30.0 kg/m2 
(3 , 39) ,  which i about a gain 0[ 20% or more of the ideal weight . 
The cau e of obe ity are many and multi factorial . Factors contribution to the development of 
obesity may be influence by one or more of the fol lowing: 
1 - The imbalance o f  intake dai ly  calories:  Obesity is the result of the increased intake of 
dai ly  calories compared to the energy l1eed of the individual . The net increase in 
calorie wi l l  be deposited in the body as fat ( L  1 ,  1 2) .  
2- Culture :  People  are usual ly served l arge amounts of foods that are most readily 
avai l able instead of  choosing foods that are most nutritious. That 's  why Today's 
cultu re promotes eating habits that leads to obesity ( 1 2) .  
3 - Gender: M usc le  uses more energy than fat .  Men have more musc le than women, and 
burn 1 0  percent to 20 percent more calories than women do at rest. For this reason, 
women are more l ikely to be obese (6).  
4- Age: The amount of musc le  in human body tends to decrease as we age, and fat wi l l  
accounts for a greater percentage of weight. This  lower muscle mass leads to a 
decrease in metabol ism and lower glucose uptake. In addition metabol ism also slows 
with ageing. Taken together, these changes reduce calorie needs. I f  food intake is not 
adj usted, human body wi l 1  gain weight ( 1 1 ) . 
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5- Honnonal imbalance: Homlonal and metabolic di ea es  uch as  Cushing Syndrome 
may contribute to weight gain and obesity ( 1 4, 1 5 ) .  
6- Gene play a part in ho\ human body balance calorie and energy. As of October 
2005, 1 76 human obesity cases due to single-gene mutation in 1 1  different genes have 
been reported ( 1 6) .  Genes can make persons more susceptible to gaining weight, by 
influencing the amount of body fat and fat distlibution. Chi ldren whose parents are 
obese al o tend to be overweight. Genes can also play role in laziness lethargy and 
lack of movement ( 1 3 ) .  
7- Emotional or Psychological Factors: Food is o[ien a source of solace or celebration. I f  
w e  celebrate w e  may g o  out to a big dinner. I f  a friend i s  grieving, we bake them a 
pie. The relationship between obesity and psychological status is very strong and vary 
from person to person, some people eat greedily in the case of joy, and others eat very 
large amounts when they face a speci fic problem, whi le others abstain from food 
completely and get the loss of many of the weight when exposed to emotional 
problem ( 1 7) .  
1 1 . 2 .  C o m pl icat ions  o f  o besity 
According to the 2002 WHO World Health Report, overweight and obesity lead to 
adverse metabolic effects on blood pressure, cholesterol ,  triglycerides and insul in resistance. 
Risk of coronary heart disease, ischaemic stroke and type 2 diabetes mel l i tus increase steadi ly 
with increasing B M ! .  Raised BMI also increases the risk of cancer of the breast, colon, prostate, 
endometrium, kidney and gal lbladder ( 1 3 ) .  
1 0  
There i a 11 lne- ear reducti n in l i fe expectancy among t obese patients, the risk being 
markedl ampl i fied i f  they al 0 moke( 1 3 ). Generalized obesity ( fat distributed around the whole 
body) re 'u lts in al terat ions in blood circulation and heart function, whi le central/abdominal 
obe 1tl' ( fatne mainly around the che t and abdomen) further restrict chest movements and 
alter breathing function. Fat arow1d the abdomen i al 0 a major contributor to the development 
r diabete , hyperten ion, and alterations in blood l ipid (triglycerides and cholesterol )  
concentrat ion ( I  ) . 
1 1 .3 . O besity a n d  d i a betes m e l l i tu s  
Mortal ity i ign ificantly higher among subjects with greater than average body weight 
compared to those with less than average body weight. In fact many studies have reported 
a ociation between diabetes and obesity ( 1 8) .  Although an inherited l iabi lity to develop diabetes 
i probably the most: impOliant factor in  the etiology of type 2 diabetes. Obesity and diabetes are 
separate and distinct risk factors for ischemic heart disease and their combined presence in the 
obe e diabetic person may be part icularly lethal .  Most diabetic patients die from ischemic heart 
disea e. It is uncertain whether the risk of death from ischemic heart disease can be reduced by 
treatment with either insul in or oral hypoglycemic agents. The risk of death from ischemic heart 
disease can ,  howe" er, certain ly  is diminished by reducing body weight ( 1 8) .  
1 1 .5.  E p id e m io logy of O besity i n  the  UAE 
Obesity i s  cun'ently an  escalating epidemic in many countries in the world inc luding the 
Arabian Gulf  region. The United Arab Emirates enjoys a high income per capita, which is 
considered among the highest in the world ( 1 9) after oi l  production which began in the 1 960s. 
Tremendous growth in population and urbanization also accompanied changes in the pattern of 
l i fe .  The country has undergone significan t  changes in nutritional and l i fe style habits. 
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uch change are expected to have an impact on the magnitude of chronic diseases 
including obe ity. 7 1 0'0 of married women and 56% of married men were found to be obese ( 1 9) .  
However, the problem of obe ity and related diseases in the United Arab Emirates are not 
l im ited to citizen \ ho make up les than 20° 0 of the population. The country's development 
depend heavi ly on expatriate workers, mo tly from Bangladesh, India, Islamic Republic of Iran, 
Pakistan, the Phi l ippine , and other Arab countri es . Obesity was common in all groups. 
pproximately three-quarters of all were either obese (BMI  2: 30) or overweight (BMl  25-29) 
(20). 
The World Health Organization repOlted that the prevalence of obesity has reached 
alarming numbers globally. It was estimated that in 2005 , 1 .6 bi l l ion adults, worldwide, are 
overweight. includi.ng 400 mi l l ion obese. A study publ ished in year 2000 reported that more than 
50°'0 of men and women in the UAE are either overweight or obese (20). These rates are also 
increa ing in other countries in the region. 
The Department of utri tion and Health at the UAE University in AI Ain reported that 
about a quarter of chi ldren between the ages of 8 and 1 2  years old are overweight (8) ,  The 
prevalence of obesity is increasing rapidly in the United Arab Emirates (UAE) especially among 
females. A recent study showed that the prevalence of obesity was associated positively with age 
(young female) and negatively with the degree of education (2 1 ) , Thus prevention programs 
should begin in chi ldhood, since 2 1  % of women are already obese by the third decade (2 1 ) . In  
addition, The Centre for Arab Genomic Studies of the United Arab Emi rates atlliow1ced that the 
rate of obesity among UAE nationals amounted to nearly 70% of the total citizens, which is  
indicator of risk (22.  23) .  Therefore, only prompt action wi l l  prevent the preeminent burden to 
the health  services in the near future (20). 
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I I I . Pa n c reas 
III. 1 .  H i  tology 
The pancreas located on the posterior body wal l ,  deep to the peritoneum, and consists of 
four r gion : unc inate proce head, body and tai l .  It is about 25  cm long, S cm wide and 1 to 2 
crn thi k, and it weighs approximately 1 50 g. I ts flimsy connective tissue capsule fonns septa 
which ubdi\'ide the gland into lobules. The vascular and nerve supply of the pancreas, as well as 
y tern of  duct travel in these cOIUlective tissue compartments. The pancreas produces 
ex.ocrine and endocrine secretions. The endocrine component of the pancreas, islets of 
Langerhans are cattered among the exocrine secretory acini  (24). 
I I I .2 .  E n docri n e  Pan creas 
The pancreas consists of two functional ly di fferent organs : 
1 .  The Exocline pancreas - the major digestive gland of the body. The major role of the 
products of the exocri ne pancreas ( the digestive enzymes) is  to process ingested foodstuffs 
for absorption (25 ) .  
2 .  The  Endocrine pancreas - i s  the source of insu l in, glucagon, somatostatin, and pancreatic 
polypeptide.The honnones of  the endocrine pancreas modulate the aspect of cel lu lar 
nutrition from rate of absorption to cel lu lar storage or metabol ism of nutrients. The 
dysfunction of the endocrine pancreas or abnonnal responses to its honnones by target 
tissues may resul t  in serious disturbances in nutrient homeostasis, inc luding the important 
c l inical syndromes grouped under the name of diabetes mel l itus (3 ) .  The endocrine pancreas 
consists of  0 .7  to 1 m i l l ion is lands of smal l endocrine glands. The islets of Langerhans 
scattered within the glandular substance of the exocrine pancreas. 
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The i let le\ el compri e of 1 - 1 . 5°,0 of the total rna of the pancreas and weighs about 1 -2g in 
adult humans ( 3 ) .  
I 1 1 . 3 .  I n s u l i n  
I n  ul in i a p r  tein with 5 1  am l l10 ac ids, contained within two di-sulfide chains: The 
molecular weight of human in u l in  is 5808 Da. Endogenous insulin has a circulatory half l i fe of 
, -5 minutes. It is catabolised mainly by insulinases in l iver, kidney and placenta. Approximately 
50° ° of  in ul in i s  removed in a single pass through the l iver. 
The human pancreas secretes around 40-50 units of insul in per day in normal adults. 
P lasma glucose levels below 80- 1 00 mg/dl (4.4-5 .6 mmollL) do not stimulate insul in release. It 
ha been confinued that the presence of glucose i requi red ( in-vitro systems) for most other 
known regulator of insu l in  secretion to be effic ient in reaction to exogenous stimuli (3) .  Glucose 
i the mo t effective stimulant of insul in release. G lucose is known to enter the pancreatic B cel l  
by pa sive diffusion, which is  faci l itated by a specific membrane protein cal led glucose 
transporter-2 . By good qual i ty of its relatively low similaIity for glucose, this protein is more 
effective in  fac i l itating the transport of glucose during postprandial hyperglycemia than at the 
lower levels of blood glucose during an overnight fast (3) .  
I nsul in action begins when insul in binds with the receptor on the surface of target cel l 
membrane. Many ce l ls  of the body appear to have spec ific cel l surface insul in receptors. I n  fact, 
l iver and musc le  cel l s, i nsul in binds with these receptors to bigger biological response to the 
honnone .The fi rst major organ reached by insul in via the bloodstream is l iver. In the l iver, 
insul in increases both protein and triglyceride synthesis aI1d VLDL formation. It also inhibits 
g luconeogenesis and promotes glycolysis through its effects on enzymes of the glycolytic 
pathway (3 ) .  In addit ion, insul in inh ibits catabol ism and acts to reverse the catabol ic events of 
the post absorptive state by inhibiting hepatic glycogenolysis and cytogenesis. 
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The econd organ reached by insul in i mu cleo lnsulin promote protein synthesis in 
mu de by increasing the amino acid tran port and timulating ribosomal protein synthesis. In 
addition, in u l in pr motes gl cogen ynthe i and restores glycogen stores, expended during 
mu c le acl i\  ity. Therefore by in reasing glucose transport into the G lycogen ynthesi IS 
enhanced b inhibiting the acti ily of glycogen phosphoryla e. On the other hand insulin act to 
elevate tligl ceride torage in adipocytes by a number of mechanisms 
I l I .4.  G l ucagon 
Pancreatic glucagon i a single chain polypeptide, which consists of 29 amino acids with 
a molecular weight of 3485 Da. It is  synthesized in the cel l s  of the islets of Langerhans and 
d riyed from a 1 60-amino-acid precursor molecule, which is five to six times bigger than 
g lucagon. Glucagon secretion is i nhibited by glucose - in contrast to the effect of glucose on 
insulin ecretion. 
G lucagon is  a humoral factor for the production of energy avai lable to the t issues 
benveen meals .  When ingested food is not avai lable for absorption, glucagon stimulates the 
breakdown of stored glycogen. It maintains the hepatic output of glucose. Compared to insulin it 
promotes energy storage in a variety of t issues. The l iver represents the major target organ for 
glucagon because of its geographic c loseness to the pancreas with portal vein glucagon 
concentrations reaching as high as 300-500 pg/ ml ( 1 00- 1 66 pmollL)(3,26) .  
m . s. So m a tosta t i n  
The gene for somatostatin is  located at the long ann of  chromosome 3 .  I t  codes for 1 1 6-
amino-acid peptide, pre-pro-somatostatin from which carboxyl tenninal is cleaved with 
somatostat in, a 1 4-arnino acid cyc l ic polypeptide with a molecular weight of 1 640 Da. I t  was 
first identified in the hypothalamus and gets its name because of its abi l ity to inhibit release of 
growth honnone (pituitary somatotropin) .  
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ince that time, omato tatin has been ident i fied in a number of tissues, including many 
areas of the brain, in the ga trointestinal tract, pancreas, central nervous syst m and the pancreas . 
omato tat in acts in se\ eral ways to restrain the movement of nutrients from the intestinal tract 
into the c irculation. It prolongs ga tric emptying time, decreases gastric acid and gastrin 
production. It d iminishe pancreatic exocline ecret ion; decreases splanclmic blood flow, and 
delay xylo e ab orption . 
1 1 1 . 6 .  P a n c reatic Polypeptide 
Pancreatic polypeptide C PP)  is a 36 amino-acid peptide with a molecular weight of 4200 
Da. We know l itt le about its biosynthesis. The circulating levels of the peptide increases in 
response to a mixed meal . In healthy SUbjects, basal Ie els of PP can average up to 24 ±4 pmol/L 
and it may increase due to a range of factors inc l uding old age, alcohol abuse, diarrhea, chronic 
renal fai l ure, hypoglycemia and other inflanunatory disorders. Values above 300 pmoll L are 
found in most patients with pancreatic endocline tumor such as glucagonoma or vipoma and in 
al l patients with tumors of the pancreatic F cel l .  Mainly 20 % of patients with insul inoma and 
one - third of those with gastrinomas also have PP plasma concentrations of greater than 300 
pmolfL (3) .  
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I V .  Ad i pose t i ssue  
I V . l .  E n doc r i ne  a d i pose t i  sue 
Adip se t i  ue insulates and cushions the body and store free fatty acids after food intake. 
Thi fatty acid i relea ed when the body in the fasting state. This old definition of adipose tissue 
role \\"a replaced by new discovery of its endocrine role (27) .  In early 1 987, adipose tissue was 
identi fied a a maj or site of production for adipsin, an endocrine factor that is markedly down­
regu lated in rodent obesity (28) .  The characterization of leptin, in adipose tissue, in 1 994 
tabl i  hed the adipo tis ue a an endocrine organ (28) .  It is a wel l  accepted fact that adipose 
tis ue play a role  in the hOTInonal regulation of body homeostasis (29). The tern1 adipokines is  
u�ed to describe hormone released from adipose t issue such as leptin, adiponectin, resistin and 
\ isfatin (30) .  
Adipose t i ssue produces bioactive peptides (adipokines) in  olved in metabol ism of 
glucose, l ipid and in the regul ation of inflammation, coagulation and blood pressure (27) .  
Howe\ er, the main regulator of adipocyte fat content is insulin (27) .  Adipose tissue expresses 
numerous receptor that al low it to respond to signal s from traditional hOTInone system, which 
explain the current iew of  its endocrine role  of sending out and responding to signals that 
modulate in u l in sensitivity and i mmunity (3 1 ,  28) .  
The assoc iation between accumulation of  visceral adipose tissue and insul in resistance is  wel l  
estab l ished in  the etiology of  obesity and diabetic mell itus (32) .  
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I V . 2 .  V i  fa ti n 
Ten ear ago a protein ecreted by lymphocyte \Va identi fied and cal led pre-B cel l 
c 1011 enhancing factor 1 ( PPEF 1 )  ( 33 ) .  PPEF 1 has recently been renamed visfatin and shown to 
be released by adipocyte and increa ed in isceral adipose tis ue compared with subcutaneou 
adipo e ti ue (33  35 ) .  
i fatin was first identi fied in 2005 as  novel member of adipocytokine family (37)  with a variety 
of actions. inc luding the fol lowing: 
a- ting as biomarker of acute lung injury. 
b- Influence infected fetal membranes. 
c- Inhibiting neutrophi l ic apoptosis in experimental inflammation and c l inical sepsis 
(36) .  
d- Participating in the maturat ion of vascular smooth muscle cel l s  through a NAD+ 
dependent mechanism ( 3 7) .  
e- Participate in the etiopathology of metabol ic  syndrome (38,  39) .  
I t  was reported that the concentration of visfatin correlated positively with fat mass in human 
(34), upporting previous reports that demonstrated a correlation between plasma visfatin 
concentration and obesity ( 33 ) .  However, the relationship between obesity and elevated plasma 
visfatin levels has not been confirmed (35 ) .  Moreo er recent studies showed that visfatin level 
may be related to visceral obesi ty in man and may account for variation of glucose in individuals 
(40) . A study perfonned on Chinese individual s comparing metabol ic parameters to visfatin 
concentration found that visfatin concentration is  higher in individuals with type 2 diabetes 
mel l itus compared to healthy control  subjects (34) .  
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y ith every year, more and more tudies report that in various in ul in sensi t ive ti sues such as 
1 1 \  er, IUU c le and fat, \ i fatin exerted in u l in mimetic effects (33-34,-+ 1 ), because it bind and 
activate the in ul in recept r in diabet ic type 2 (42 ) .  Independently, visfatin is associated with 
\Vai t-hip ratio and body 111a s index (BM! )  (43 ), in ulin resistance (44), hyperandrogenism in 
lean patients (44), and dysfunction in early diabetic nephropathy (45 ) .  A recent study perfonned 
in 200 conc l uded that visfati11 was ign ificant iy lower in the gestational diabetes mel l itus 
pregnant women than pregnant wom n with nonnal glucose tolerance (46). 
I V.3.  Ad i po n ecti n 
Adiponectin is a 244 amino acid honnone that is produced in adipose tissue (visceral, 
ubcutaneous and bone marrow fat depots (47-4 , 50). Various names such ACRP30, APM 1 ,  
GBP28 ,  ADI POQ ha e been u ed to describe adiponectin (47). The recent discovery of two 
adiponectin receptor i sofom1s has given more interest into the differential effects of various 
adiponectin i ofonns. Adiponectin acts as an insulin ensitizer by enhancing fatty acid oxidation 
in keletal muscle and suppressing hepatic glucose production in various animal model s  (52) .  
Moreover, i t  was found that adiponectin i s  lower in males than females (5 1 ) . 
The finding that the concentration of adiponectin i higher in persons with type I djabetes 
than in non-diabetic persons and type 2 diabetes ( 5 1 ,  20) opened the door to study the detailed 
effect of this peptide tarting with epidenUological data present in 2006. I t  was shown that low 
level of adiponectin at basel ine is  associated with increased risk to developing type 2 diabetes 
(53 ) .  
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In Januar 2009 another tudy demonstrated for the fi rst time that adip nectin levels in 
ubject with type 2 diabetic nephropathy are strongly positively associated with fasting in ul in 
le\ el  and in ul in re i tance (54)  and high adiponectin I vel is  as ociated \ i th sign.ificantly 
reduced ri k of DM de\ elopment .The level of  adiponectin inversely correlated with body rna 
index and body fat di tribution (55 ) .  In a study of obese child and its relation of adiponectin, 
body fat ,  g nder and puberty, i t  wa demonstrated that increase in adponectin concentration is 
a ociated with a igni ficant weight loss and improvement of insulin resistance ( 57) .  In vivo and 
in vitr tudies have shoy n that adiponectin level is inversely related to oral glucose tolerance, 
in u l in ensiti ity and cardiovascular problems (47, 56) .  
CUlTently, adiponectin has been suggested as a new drug in the treatment of 
atherosc lero is  and metabolic syndrome such as visceral obesity, and insul in resistance in type 2 
diabete mel l itus (49). 
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OBJECTIVES 
2 1  
O BJ ECT I V E S  
isfatin and adiponect in, ecreted by adipose tissues, are signal ing molecules 
implicated in the development of ob sity and consequently  type 2 diabetes (64) . The aim of 
thi study i to examine the e flect of isfatin and adiponectin on the metabol ic parameters 
(weight, gluco e, oral gluco e tolerance test) of Goto Kakizaki (GK) rats, an animal model of 
type 2 diabete . 
The spec ific  obj ectives are as fol lows: 
1 .  I mm unolocal ize visfatin and adiponectin in the cytoplasmic organel les of adipocytes 
and pancreas of G K  and Wi star rats. 
2. Investigate the hort- and long-term effect of visfatin and adiponectin on the pattern 
of distribution of insul in, glucagon somatostatin and pancreatic polypeptide in GK 
and Wistar rats. 
3 .  Detennine whether intraperi toneal injection o f  visfatin and adiponectin w i l l  lead to a 
further enhancement of insul in resistance and worsening of the metabolic parameters 
in G K  and Wistar rats .  
4 .  Examine the relation h ip between visfatin and adiponectin, obesity and type of 
diabetes. 
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I .  M a teria ls 
1 . 1 .  E x peri m e n tal  a n i m a l  
Goto Kakizaki (GK) and Wi tar male rat ( WR )  were breaded in the Animal Hou e 
Fac t l i t; in the Faculty of  edicine & Health Science , UAE University. All rats were housed i n  
a temperature (_SOC) and hwnidity control led rooms and 1 2  hours l ight and dark periods. The 
animal were fed on tandard laboratory animal chew with food and tap water ad l ibitum . 
The rats within age of two and three month, were divided in to l1 1ne groups each 
con i t ing of 1 2  rats :  I -GK nonnal, 2 -GK treated with isfatin, 3-GK treated with adiponectin 
4-WR diabet ic treated with visfatin, S-WR diabetic treated with adiponectin, 6- WR nonnal 
treated with visfatin, 7- WR nonnal treated with adiponectin, 8-WR diabetic untreated and 9-WR 
nonnal untreated. Diabetes in  WR was induced by a single intrapelitoneal injection of 
streptozotocin (60 mg kg- I ) prepared in S mM citrate buffer pH 4.S0 (59). The animals were 
con idered diabetic i f  the random blood glucose levels were equal to or more than 2S0 mgldl .  
One week from induction of diabetes, 3 groups received intraperitoneal injection of  ( 1 0  ng/kg 
body weight) adiponectin.  I n  addition, another 3 groups were treated with intraperitoneal 
injection of 1 0  ng/kg body weight of visfatin) .  Al l  animals from al l  groups were sacrificed after 
1 4  weeks of treatment for blood plasma biochemistry analysis. The pancreas was rapidly 
removed and representati e fragments were taken to be used for i llli11unohistochemical, 
i lllinunofluorescence and electronmicroscopy studies . 
1 . 2 . E x p e r i m e n t a l  c h e m ica ls  
Standard laboratory chemicals used for process 1 l1g of  tissues and other laboratory 
tedmiques were acquired from either BDH or Sigma. Al l  other kits were acqui red from Phoenix 
(visfatin ( 1 4 1 - 1 68)  (Human), adiponectin recombinant (rat), insul in and glucagon E IA, mouse­
monoclonal anti-adiponectin, antiserum), or Dako (guinea-pig anti insu l in, rabbit anti-hwnan 
glucagon, rabbit anti-human somatostatin, or Jacksons Laboratory (anti rabbit RRX and anti 
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gUlm.:a-plg F IT ). Beckman 'oul ter reagent and Real-time P R ki t , Taq�lan It Gene 
ExpreSS ion '. ay ( pp\ t\.:d B lOsy tcm , 
1 .3 .  E � pe r i m e n ta l  eq u i p m e n t  
I I  eqU Jpmcnt· Cor i l11munohi tochemi try and electron micro copy were a\ at lab le  i n  the 
Facu lty of 1edic i l1l; Health C lence \\ h i l e  bi  chemical Analy i perfon11ed at C l in ical 
hemi try Department at I in Ho pita! .  
I I . l\ l ethods 
I l . l .  I n  v ivo stud ies 
I I . 1 .a .  "'eight  mea u rement 
The weight of nonnal and vi  fati n  and adiponectin-treated rats were taken weekl y  and 
re orded. The a\·erage weight for ach group \Va calculated. 
I I . 1 .b .  B lood gluco e 
B lood g luco e le\ el mea ured from the tai l vein of n0n11al and treated GK and Wi tar 
rat at weekly i nterval u ing a L ife can G lucometer (Mi l p itas, CA, U A) to exami ne whether 
\·i fat in and adiponect in ha any effect on fa t ing b lood glucose value when compared to 
untreated rat . I I  rats were fa ted ovemigh t  ( 1 2  hour ) for the measurement of b lood g lucose. 
I I . 1 .c. G luco e tolerance te t 
At the end of the experiment ( 1 4 week ) ,  control and treated rats were fa ted overn ight 
( 1 2  hour ) prior to the te t .  Each rat was g i\  en an oral g lucose load, 2g/kg body weight (59) .  
B lood ample  were col l ected from the ta i l  vein at t ime 0 (prior to the g lucose load), 30, 60 and 
1 20 m inute after the g luco e l oad. 
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I l . l .d .  Ti ue col lect ion and ti ue proce i ng  
t t he  end of the experimc.:nt. nom1al and treated rat were acn ticed for b lood p Ia  ma 
bl  cheml try analy. i and col l ect ing of pancrea. and fat ti ue. long abdomi nal l I1c i i on \Va 
made and th pancrea and c.:pid idymal fat h ue were qu ick ly  remo\ed. Whi le  ubcutaneous fat 
tl 'ue \\ a co l lected beneath the rat k in .  Al l coil cted t i  ues trimmed f connecti \  e ti ues and 
fi ed o\elll i ght i n  Zamboni '  fixat ive (62) .  The t i  ue amples were later dehydrated i n  graded 
c ncentrat lOn of ethanol .  The pec imens were changed every 2 hour i n  70�0 and 95° 0 and 3 
change i n  ab o lute ethanol for 2 hour . After dehydration the pec imens were c leared i n  xylene 
and 'ub 'equent l y  embedded i n  paraffin wax at 55°C. ection of  6-7 11m thickne were cut on a 
microtome. and p l aced i n  water bath at 49°C. Th reafter. they were tran ferred onto m icroscopic 
l i de . \\ h i ch  were dried in an oven at 60°C for 30 m i n  to enhance attachment of ect ion . 
n.2 .  E t i m at ion of  i n  v itro p a n c reatic  i ns u l i n  and glu cagon relea e 
I n  th i  experiment, 6 rat from untreated group were u ed. The pancreas wa removed 
and p l aced i n  ice-co ld P B  (phosphate buffered al i ne). The pancreas w a  trim med free of 
adherent fat and connect ive ti ue and cut i n to smal l fragments (0 . 1 g) and p laced in 2 ml g lass 
v ial conta in ing 1 m l  of P B  and pre-i ncubated for 30 min in a water bath at  37°C in  order to 
wa h away any enzyme and hormones due to cutti ng of the t issues. After the pre- incubation 
period. the P B  o lut ion wa dra ined and the fragments were subsequent ly  i ncubated for 1 h \ i th  
d i fferent concentration of v i  fati n  and adiponect i n  ( l 0- 1 2, 1 0-
9 and 1 0-6 M) .  In  order to examine  
the  mechan i ill of act ion of adiponecti n  and i fati n  pancreati c  t i  ue  fragment were a l  0 
l I1cubated wi th e i ther atropine ( 1 0-6 M) ;  propranolo l  ( 1 0-
6 M) ;  yohimbine ( 1 0-6 M); or d i l t i azem 
( 1 0-6 M) .  
D uring  the  i nc ubat ion period each v ia l  wa gas ed wi th  95°'0 oxygen and 5% carbon 
d ioxi de every 1 0  m i n .  t the end of experiment the ti ues were remo ed b lotted weighed and 
i ncubat ing  solut ions tored at -20oe for i n  u l i n  and glucagon as ay. 
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I I .2 .a .  In  u l i n  a ay 
In  u l i n  \\ a detelTn i ned u ing  DakoCytomation I nsul in E L I SA which was ba ed on two 
monoc lonal ant ib  d i e . imu l taneou i ncubation of sample ( plasma or sol ut ion) and enzyme­
label l d anti bod i n  a microplate microwel l  coated with a pec ific ant i - i nsu l i n  antibody fonl1s a 
compte . s imp le  \ a h i ng  step removes unbound enzyme- label led ant i body. The bound 
conjugate i detected by react ion with the substrate 3 ,3 ',5 ,5 '-tetramethylbenzid ine (TMB) .  The 
react ion i stopped by addi ng ac i d  to gi e a colorimetric endpo int that is read 
pectrophotometrical l y. The i nc l us ion of cal i brators of known insu l i n  concentration i n  the assay 
al low a ca l ibration  curve to be con tructed from which the level of i nsul i n  in samples can be 
detenl1ined. 
I I .2 .b. G lucagon assa 
G lucagon was deteml i ned using Phoenix E nzyme i mmunoassay k i t .  The assay protocol 
tarted wi th add i ng of 50Il L/we l l  of standard sample  po i t ive contro l ,  25 1l L  primary antibody 
and 251lL b iot iny lated peptide  to immunop l ate and then i ncubation at room temperature for 2 
hour . T he i mmunoplate was washed 4 t imes wi th 350 ilL/we l l  of I x assay buffer fol l owed by 
adding  1 00 ilL/we l l  of SA-HR P  (streptavid i n- horseradish peroxidase) solut ion then i ncubated 
at room temperature for 1 hour fol l owed by washi ng the immunoplate 4 t imes with 350 ilL/wel l 
of 1 x assay buffer. After that 1 00 ilL/we l l  of TMB (substrate sol ut ion) was added fol lowed by 
i ncubation at  room temperature for 1 hour us ing acetate p late sealer. Reaction teD11inated wi th 
1 00 ilL wel l of 2 He l  added. The i mmunopl ate was loaded to the reader and absorbance was 
read at 450 nrn. 
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1 1 .3.  I m m u n o h i stoc h e m i stry 
cction were d -paraffinized with xylene two time (5 min each) and then transferred 
into ub,olute ethanol two tim (5 min each) .  After that the ections were incubated in 0.30 0 of 
hydr gen peroxide olution in methanol for 30 min to block the activity of endogenous 
p r xida e. The tis ue were then hydrated in descending concentration of ethanol and washed 3 
time in PBS (phosphate buffered saline) for 5 min each. After washing in PBS the tissue were 
marked arolmd with a Dako pen to prevent solutions draining away from the tissue ection. 
The staining procedure was tarted by incubating the sections with blocking reagent for 
30  min. fier that the blocking reagent was drained off and appropliate di lution of the pIimary 
antibodies were appl ied and incubated at 4°C for 24 hr. On the fol lowing day the section were 
incubated at room temperature for I hr. The s l ides were then washed 3 times in PBS for (5 min 
each) and incubated with pre diluted biotinylated anti-guinea- pig or anti-mouse or anti -rabbi t  
IgG ( igma, S t  Louis, MO, USA)  for 1 hour, then washed in PBS 3 'times (5 min  each) and 
ubsequ ntly incubated in  streptavidin peroxida e conj ugate (Sigma) for 1 h. After a [mal wash 
in PB 2 t imes (5 min each), the peroxidase activity was revealed by incubating the sections in 
3 .3diaminobenzidine tetrahydrochloIide DAB (Sigma) in PBS for (5 min) .  The sl ides were then 
wa hed for 5 min under running tap water and counterstained with haematoxylin for 1 5  seconds 
and washed bliefly in tap water. Then they were differentiated in acid ethanol and washed for 5 
min under running tap water, then dehydrated in ascending grades of ethanol ,  and subsequently 
cleared in  xylene for longer time to dissolve the Dako pen mark. The tissues were subsequently 
mounted in DPX. S l ides were examined under microscope and immunopositive areas of the 
tissue ection were photographed . 
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1 1 .4 .  I m m u n ofl u o re cenece 
I o lat d pancreatic t i  ue were retrieved fi xed and embedded in paraffin as de cribed in 
ection or ti ue col lection and tis ue proce ing. Sections were de-paraffinized in xylene, 
h 'drated in de c nding concentration of ethanol (3 min each) and washed 3 time in PBS for ( 5  
min each) .  fier washing i n  PB , the tissue was marked around with a Dako pen to pre ent 
olutions draining a\ ay from the tis ue section. The staining procedure was started by incubating 
the ections with blo king reag nt for 30 min. After that the blocking reagent was drained off 
and appropriate di lution of primary antibodies were appl ied and incubated at 4°C for 24 h. On 
the fol lowing day the sections were incubated at the room temperature for I hour. The s l ides 
were then wa hed 3 t ime in PBS (5 min each) and incubated with secondary antibodies 
conj ugated to either F ITC or TRITC for 1 hour and washed in PBS (3 times 5 min each).  
ections were then mounted in using mounting media and viewed and photographed under 
i kkon Fluorescence microscope . 
1 1 .5 .  Bioc h e m ica l  a n a lysis  
U ing Beckman Coulter UniCel DxC 800 System(s) at  Cl inical Chemistry section at 
Al Ain Ho pital the fol lowing p lasma tests were performed (60,58) :  
1 .  Blood urea nitrogen (BUN) measured by means of an enzymatic conductivity rate 
method. 
2 .  Creatinine (CRE)  measured by  means of the Jaffe rate method. 
3 .  Alkal ine phosphatase (ALP) measured by a kinetic rate method using a 2-amino-2-
methyl- I -propanol (AMP) buffer. 
4 .  Alanine aminotransferase (ALT) plasma, aspartate aminotransferase (AST), Amylase 
(AMY), l actic dehydrogenase (LDH) and GanllTIa�glutarnyl transferase (GGT) 
measured by an enzymatic rate method. 
5 .  Cholesterol (CHOL), H D L  cholesterol, Triglycerides (TG) and phosphorus (PHOS) 
by a t imed-endpoint method. 
6 .  Sodium by indirect potentiometry uti l izing two glass sodiwn electrodes (one acts as 
the reference electrode) . 
7 .  Albumin (ALB) by means of a bichromatic digital endpoint methodology using 
bromcresol purple (BCP) reagent. 
8 .  Total protein (TP)  measured by means of a rate biuret method. 
9 .  Chloride measured by indirect potentiometry methode uti l izing a sol id state chloride 
electrode in conjunction with a g lass sodium reference electrode (CI) .  
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1 1 .6 .  E l ectron m i c roscopy stud ies 
Pancrea ii'agments were trimmed free of adherent connective tissue and cut into mal l 
pie e of  2 mm and fixed ovemight in fresh ly prepared Kamovsky fixative (Kamovsky, 1 965) .  
They were later \\ a h d 3 times in 0. 1 M Phosphate buffer and postfixed in I % osmium tetroxide 
for I hour. After po t- fixation, they were washed 5 times in buffer and dehydrated. Dehydration 
of tissue wa done in ethanol series, with a single change of 1 5  min in 30%, 50%, 70%, 95% and 
4 change in absolute ethanol for 1 5  min each. After the dehydration step, the samples were 
c leared in propylene oxide (2 changes of 1 5  min each) and tran fened to 1 :  1 mixture of 
propylene oxide and re in for 1 hour and later transfened to 1 :  2 mixtw'es of propylene oxide and 
re in. One hour after the 1 : 2 mixture, the tissues were infiltrated with resin ovemight. The 
ample were l ater embedded in resin using moulds; polymerisation of the resin block was 
completed in 24 hours at 5 5°C. The blocks were trilmned and 1 11m semi-thin sections were cut 
with g las knives on an ultra microtome (Reichert Ultracut S, USA) and sections were 
transfen'ed onto drops of  water on a microscope sl ide using watchmaker's forceps. The s lides 
were stained with tol udine blue and observed under electron microscope to locate the islets of 
Langerhans . 
I I .7 .  I m m u n oelectro n  m i c roscopy 
The pancreas was trimmed free of adherent fat and connective tissue and cut into smal l 
pieces of  2 mm3 and fixed ovemight in freshly prepared mix of (4% parafonnaledhyde and 0.05 
% g lutaraldehyde for at 4°C Thereafter, they were washed 3 times in 0. 1 M phosphate buffer and 
dehydrated in  concentrated ethanol selies with a single change of 20 min in 70%, 95%, 95%. 
After the dehydration step, the tissue samples were transferred to a 1 :  1 mixture of 95% ethanol 
and res in (LR White) for 1 hour for infi ltration and later transfened into LR White resin over 
n ight at 4°C. In the next day, the t issues were transfened from resin to gelatin capsules under UV 
l amp for 24 hours to al low for polymerization. The tissue blocks were further trim ed for u ltra­
thin sectioning. Ultra-thin sections were cut at a thickness of 80 11111 by a diamond kni fe. The 
sections were transferred onto 300 mesh copper grid by a wire loop. The grids were dried on a 
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fi l ter paper and tained with uranyl acetate for 30 min and \Va hed 5 times in fi ltered di t i l led 
\\ ater. To further enhance the contrast, the ections were stained in lead citrate for 3 min and 
\\ a hed 3 t ime in fi ltered di t i l led water. The dried grid were observed on transmission electron 
mIcro cope (Phi l ip M 10, Eindhoven, Hol land) and photographed. 
1 1 .8.  Q u a n tificat ion of gene e x p ress ion in p a n c reatic tissues 
The relative quanti fication of genes wa perfom1ed using real-time PCR. Total RNA was 
extracted from rat pancreat ic tissues using RiboPure (Appl ied B iosystems, Forster City, CA, 
USA) acc rding to the manufacturer' reconu11endations. The concentration and the purity of the 
RN ample wa detem1 ined by measuring absorbance at 260 ill11 and 280 nm using the 
1 anoDrop 1 000 Spectrophotometer. cD  A synthesized using High Capacity cD A Reverse 
Tran cription Kit with RNase. 
Gene expres ion a says using TaqMan labeled primers and probes for the requested target 
gene (insul in receptor gene, pancreatic and duodenal homeobox I ,  GLP- I R  gene, heme 
oxygenase Homx- l ,  glutathione peroxidase 2, HSP70) was done. The endogenous control 
was beta-actin. By using an endogenous control as an active reference normalizing 
quantification of a messenger RNA target for differences in the amount of total RNA added 
to each reaction. Relative quant ification was performed using real-time PCR. In  real-time 
PCR as ays. the progress of the PCR as it occurs was monitored. Data were col lected 
throughout the PCR process rather than at the end of the PCR process. Data was analyzed by 
creating an RQ Study document using SDS software for 7500 ABI Prism Sequence Detection 
system. 
1 1 .9 .  Statist ic a l  a n a lyses 
Al l  data were expressed as mean ± SD. Student's T-test was used to analyze the 
significance of differences between mean values of different groups. A p value of less than 0.05 
was considered to be stat ist ical ly ignificant . 
3 1  
RESULTS 
32 
I .  Effect of a d i p o n ect in  and  visfat in  on meta bol ic  pa ra meters i n  
STZ- i n d u ced a n d  G K  rats 
1 . 1 .  Body weight  
F igure ( I )  ho\\ s the pattern of \\ ei ght ga in  or loss i n  d i fferent animal models  of  
d iabete dur ing 14  \\ eek. treatment \\l i th 10  ng kg bod)- \.v e ight of ad iponect i n  and v i sfat i n .  
cont i nua l  trend of  \\ e ight gai n Vv as observed i n  normal  Wi  tar rats treated \v ith e i ther 
ad i pone t in  or v i sfat i n  ( I .A) .  Ho\\ e \  er. d iabetic Wistar rats lost \\ e ight cont inuou Iy  up to 
the 6th \\ eek of treatment before sl ight l)- ga i n i ng \v eight t i l l  the end of the experiment at \\. eek 
8 ( 1 .  B) .GK rats gai ned \v e ight cont i nuousl y  throughout the course of the experi ment 
i rre pe t i \ e of \\ hether they treated \\ i th  either ad ipopnect i n  or v isfat i n  ( I .C ) .  
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Figure ( I .A )  shows the effect of v isfat i n  and ad i ponect in on bod)- \\. e ight gained or 10 t i n  
normal  W R .  I 0 s ign i ficant d i fference i n  body weight \'v as obsen ed i n  treated and control 
rat ( Data are mean ± D. n=5 ) .  
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Figure ( I . B ) ho\\ the effect of v i s fat in and ad i ponect in on bod) weight gained or lost in  
d iabetic WR.  a s ign ificant d i fference i n  bod) we ight \\ as observed i n  treated and control 
rat ( Data are mean ± D. n=5 ) .  
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Figure ( I .C )  sho\\ the effect of v i sfat i n  and ad i ponect in  on bod) \ve ight gai ned or lost i n  
G K  rats. a s ign ificant d i fference i n  body \\ eight \\ as ob en,ed in  treated and control rats 
( Data are mean ± D_ n=5 ) 
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1 . 2 .  Blood gluco e 
Blood g luco e level of  normal .  d iabet ic W i  tar and GK rats treated \'� ith or \'. ithout 
ad i ponect i n  or \ i fat i n  i ho\\ n i n  figure ( 2 ) . e i ther ad iponect i n  nor \ isfat in  ign ificant l }  
a l tered b lood g l uco e lev e l  i n  normal  Wi tar rats ( 2 .A) .  Ho\\ ever. the b lood g luco e level of 
d iab t ic  rat treated \ \  i th e i ther ad i ponect i n  or v i  fat in  \\ as ign ificantly reduced i n  week 4 of 
the experi mental period before i nc reas ing to\\ ards the end of the experiment ( 2 . B ) .  The blood 
g luco e Ie el o f  G K  rats treated ad i ponect in  and v isfat i n  \v as 10'ver  in the la t 2 weeks of the 
e:-.peri ment compared to control ( 2 .C) .  
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Figure ( 2 .A )  show the effect of vis fat in and ad i ponect i n  on blood g lucose level in normal 
and treated WR. (Data are mean ± D. n=5) 
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Figure ( 2 . 8 )  ho\\ effect of v i  fat i n  and ad i ponect in  on blood gl uco e leve l of treated 0 1 -
\\ R .  G l uco e [evel decrea ed harp l }  i n  \\ eek -+ after treatement with v isfat in  and 
ad i pone t i n .  ( Data are mean ± 0, n=5 ). O M :  Diabete me l l i tus 
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F igure (2 . C )  representat ive  the effect oh i fat in  and ad i ponect in on blood gl ucose level  of 
G K  treated rats. G l uco e Ie e l  i n  treated rat appear lo\\er  com pared to control .  ( Data are 
mean ± D. n=5 ).  
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1 .3 .  G l u cose tole ra n ce test 
F igure ( 3 )  ho\\ gl ueo e to lerance test in  animal models of 1) pe 1 ( Wistar rats ) and 
t) p 2 d iabete ( G K  rats) .  Ad iponeet in and \ isfat i n  s igni ficant ly ( p  < 0.0003 ) reduced blood 
g luco e le\  el 60 m i n  a fter g luco e chal lenge i n  normal Wistar rats ( 3 ,A). I n  d iabet ic Wistar 
rat treated \\ ith ad i ponect i n  and v i  fati n, there \\ as no s igni ficant d i fference in b lood g l ucose 
le\ el after treatment \\ i th e i ther ad i poneet in  or " isfati n compared to control ( 3 . B ) . In GK rats. 
b lo d gl ueo e \\ a i gn i fieant l )  ( p  0.005 ) 10\'v er 1 20 m in  after glucose chal lenge in both 
ad i pon t in  and \ i Fat i n  treated rats ( 3 . C) .  
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F igure ( 3 . A) depicts the effect of  v i stat i n  and adiponect i n  on  g l ucose to lerance test (GTT) 
of normal and treated WR. ote that v isfat i n  and ad i ponect i n-treated rats have better 
g lueo e hand l i ng after 60 m i n .  ( Data are mean ± D. n=5 ) 
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F igure ( 3 . B )  ho\\ the effect of v i  fat i n  and ad i ponect i n  on glucose to lerance te t (GTT) of 
treated DM- WR ( Data are mean ± 0, n=5 ) .  There \Va no signi ficant d i fference i n  glucose 
hand l i ng bet\\ een the 3 group of rats. O M :  Diabetes mel l i tus 
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Figure ( 3 .  ) depict the effect of v isfati n and ad i ponect in  gl ucose to lerance test (GTT) of 
normal and G K  treated rats. ote that \ isfat i n  and ad i ponect in-treated rats hm e better 
g l uco e hand l i ng after 1 20 m in .  ( Data are mean ± D. n=5 ) 
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I I . I m m u no h istoc h e m istry of ad iponect in  and  v isfat in in  
p a n c reatic  is lets. 
Figure (-+)  and ( 5 )  ho\\ ad i ponect i n-po i t i ve ce l l s  in the pancreas of va rio LIS animal mode ls 
of d iabete . d i ponect i n  \\ as observed i n  pancreat ic  is let cel l s  of normal and ad iponect i n ­
treated G K  rat . " here they occupy the central region.  The adm i n istrat ion of ad i ponect in d id  
not i gn i ficant l ,  enhance the  e press ion of ad i ponect in i n  the pancreat ic is let of normal 
\\ i , tar rat ( F igure 6). Figure ( -+ )  ho'v\ s ad i ponect in-posi t i \ e  cel ls  in the is lets of d iabetic 
\\ i tar rat treated \\ ith or  \\ ithout ad i ponect in .  
F igure (-+ )  repre entat i \  e m icrographs sho\\ i ng ad i ponect i n-posi t i , e  ce l l s  i n  the 
- D iabetic \ v i star rats 
8- D iabetic Wistar treated with ad i ponect i n  
* ote that the is lets of d iabetic rats conta i n  ad iponect in .  
Magnificat io n :  X 200 
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micrographs ho\\ ing ad i ponect in-posit ive ce l l  I n  the 
pancrea of: 
orma l G K  rat 
8- G K  treated \\ i th ad i ponect in  
* ote that the e:-..pres ion of ad i ponect in is  stronger i n  treated rats compared to 
contro l .  
Magn ificatio n :  X 200 
F igure (6 )  representati ve m icrographs sho\\ ing ad i ponecti n-posit ive cel ls tn the 
pancreas of: 
ormal W i  tar rats 
8- onnal Wistar rats treated \\ i th ad i ponect i n .  
* ote that the express ion of ad i ponect in  i tronger i n  treated normal v., i tar rats 
compared to contro l .  
M agn i ficatio n :  X 200 
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Figure ( 7 )  and (9 )  ho\\ i fat i n-po i t ive ce l l s i n  the pancrea of various animal 
mode l '  of d iabete . fati n  \\ a ob en. ed i n  pancreatic is let cel l s  of normal and v i  fati n -
treated G K  rats. \\ here the) occupy the central region. The adm in i strat ion of  isfat in d id  not 
ign i ficant l )  enhance the e pre ion of isfat in in the pancreat ic i let of normal Wistar rats 
( F igure8 ) .  F igure (9 )  show s v isfat i n-posi t ive ce l l  i n  the i slets of d iabetic Wistar rats treated 
\\ i th or \\ i thout \ i fat in  
F igure (7 )  representat ive m icrographs showing v isfat in-posi t i \ e ce l l  1 11 the 
pancreas of: 
A- armal G K  rats 
8- G K  treated \'v i th  \ isfat i n  
* ote that v i sfat i n  i s  present i n  the is lets of G K  rat and i ncreased tremendousl) 
after treatment .  
M a g n i ficat ion : X 200 
4 1  
A 
F igure ( 8 )  repre entat ive micrograph hO\'v ing 'v isfat in-pos i t ive cel l s  in the 
panc rea of: 
- 1 onnal W i  tar rats 
onnal W i star rat treated with isfati n 
ote that isfat i n  i present in the pancreas of Wi star rats. Treatment did not 
ign ificant l) increase i let expre s ion of 'v i fat i n .  
M agn i fication : X 200 
F igure ( 9 )  representat i ve m icrographs sho'v\ i ng v i sfat in-posi t ive ce l l s  i n  the i slet 
of: 
A- Diabet ic W i star rats 
8- Diabet i c  W i star treated \\ i th 'v isfati n 
* ot that a reduction in  the degree of express ion of v i sfat i n  i s  di cern ible i n  the 
i let . Magn ification : X 200 
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I l l . I m m u n ofl u o rescence stud ies 
l I L t .  I m m u no fl u o re cence st u d ies of  a d i po n ectin i n  p a n c reatic isl ets of  
va rious  a n i m a l  model  o f  d i a betes. 
1 l I . 1 .a .  Adiponect in  and in u l i n  
I mmunofl uorescence tudy how s that man) is let cel l s  i n  the pancreas of GK rats 
conta i n  ad i ponect in .  [an) i l et cel l s  contai n  both ad i ponect i n  as wel l a insu l i n  ( F igure 1 0) .  
Treatm I1t of  G K  rat d id not s igni ficantly i nc rea e the number of adiponect in conta in i ng 
ce l l  i n  pancreat i c  i s lets ( F igure I I ) . 
I n  a i m i lar \\ ay. normal and ad i ponect in-treated Wistar rats conta in  large numbers of 
adi ponect i n-posi t i\e ce l ls  ( F i gure 1 2 ) .  Treatment of normal Wistar rats \.\ i th adi ponect in  
i nc rea e the degree of co- Iocal izat ion bet\v een i n  u l in  and ad i ponect in (F igure 1 3 ) .  
The number of ad i ponect i n- immunoreacti  e cel l s  decreased signi ficant l) after the 
on et of d iabete in Wistar rats ( F i gure l -l ) .  Ho\\ e er. treatment of d iabet ic Wi  star w i th 
ad i ponect i n  s ign i ficant ly  increased the number of i nsul i n  pos i t ive cel l s  in  the pancreatic is lets 
of d iabet ic rats ( F i gure 1 5 ) .  
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F igure ( 1 0) representat i \ e micrographs 
sho\\ i ng i nsul i n  po i t ive- (Green )  and 
ad i ponect in pos i t ive- ( Red) cel l  in pancreatic 
i s lets of contro l GK rats. 
- I nsul in  (A lone) 
lone) 
ot that many is let cel ls conta in  both 
ad iponect in and i nsul i n .  
Magnification: X 200 
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F igure ( 1 1 )  repre entat ive micrographs showing 
i nsu l i n  pos it i v e  ce l l  (Green ) and ad i ponect in 
po it i \ e cel l ( Red ) i n  pancrea i lets of GK rats 
treated \\ ith ad iponect i n .  
- I n  u l i n  ( Alone) 
8- Ad iponect in (A lone) 
X 200 
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F igure ( 1 2 ) repre entat i \ e m icrograph 
ho\\ i ng in 'u l i n  (Green) and ad iponect in­
po it i \ e  ce l l  ( Red ) i n  pancrea is let' of 
normal Wi tar rat . 
A- I n:.ul i n  ( lone ) 
B- d iponect i n  ( lone) 
C - \,lerged 
* ote that I n  u l i n  colocal i7c \\ ith 
ad i ponect in in i let cel l  . 
Magnification : X 200 
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F igure ( 1 3 )  representat i \ e  micrograph 
i nsul i n  pos i t ive ce l l  (Green )  and ad iponect in 
pos i t ive ce l l  ( Red ) i n  pancreas i lets of nonnal 
W i  tar rats treated \\ i th ad iponect in .  
A- In u l i n  (A lone) 
8- Ad iponect i n  ( lone) 
C- Merged 
* ote that the number ofad iponect i n-posi t ive 
cel ls  i ncreased after treatment . The degree of co­
local izat ion ofad iponect in  and insul in  is 
enhanced. 
Magn ificatio n :  X 200 
-1-8 
F igure ( 1 -1- ) representati \; e micrograph 
in u l i n  po i t i ve cel l  (Green)  and ad i ponect i n  
posi t i ve  cel l ( Red ) i n  pancreas is lets of d iabetic 
untreated Wi ter rat . 
. \- I nsul in  ( lone) 
B- '\d iponect in ( Alone) 
- Merged 
Magnification :  X 200 
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F igure ( 1 5 ) representat ive micrographs sho\\ i ng 
i nsu l i n  pos it ive ce l l  (Green ) and ad iponect in  
pos i t ive cel l ( Red ) i n  pancreas i s lets of treated 
d iabet ic Wistar rat . 
A- I nsul i n  ( A lone) 
B- d i ponect i n  (A lone) 
C- Merged 
* ote that treatment \\ i th ad iponect i n  increased 
the number of i nsul i n  pos i t i v e ce l ls. 
Magnification :  X 200 
I I I . l . b. Adiponectin and g lucagon 
The pancreatic i let of GK rat conta in  g lucagon. \\ h ich appear to be more in  
number ompared to W i  tar rat ( F igure 1 6) .  d i ponect in  al 0 co-loca l i zes \\ ith gl ucagon i n  
pancreat ic i let of G K  rat treated \\ i th ad i ponect i n  ( F igure 1 7 ) .  Ad iponect in  is  present 
in pancreat ic is lets of normal Wistar rats ( F i gure 1 8 .2 1 )  but decreased signi ficantly after the 
on et of d iabete ( F igure 1 9 ) .  Treatment of d iabetic Wistar rats with ad i ponect in enhanced 
cel l u lar co-local izat ion bet\\ een ad i ponect in and gl ucagon ( F igure 20) .  
F igure ( 1 6) representat i \ e micrographs 
ho\\ i ng g lucagon posit ive ce l l  (Green ) and 
ad i ponect i n  posi t ive ce l l  ( Red ) in pancreas 
is lets of normal GK rats. 
- G l ucagon (A lone) 
8- Adiponect i n  (A lone ) 
c- l erged . 
* ote that G l ucagon and ad iponecti n-po it i \ e  
ce l l  are pre ent i n  the i lets ofGK rats 
Magnifica tion : X 200 
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F igure ( 1 7 ) representat ive micrographs sho\\ i ng 
g lucagon pos i t ive ce l l  (Green ) and adiponect in  
pos i t ive ce l l  ( Red) i n  pancreas is lets of GK rats 
treated v. i th ad i ponect in .  
- Gl ucagon ( A lone) 
B- Ad iponect in  (A lone) 
C- Merged. 
* ote that some i slet cel ls  conta in  both 
ad i ponect in  and g lucagon 
Magnification : X 200 
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F igure ( \ 8 ) representat ive m icrographs 
show ing g lucagon pos i t ive ce l l  (Green )  and 
ad i ponect in  posi t i v e ce l l  ( Red ) in pancreas 
i lets of ormal Wister rats.  
A- G l ucagon ( Alone) 
B- Ad iponect in  ( lone) 
c- lerged 
* ote that I slet ce l l s  conta in  large number of 
ad i ponect in .  
Magnification : X 200 
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F igure ( 1 9 )  representat ive m icrographs shoV'. ing 
glucagon pos i t i  e ce l l  (Green )  and adi ponect in 
pos i t ive ce l l  ( Red ) i n  pancreas i s lets of d iabet ic 
untreated Wi  star rats. 
- G l ucagon (A lone) 
8- Ad iponect in (A lone ) 
C- Merged 
* ote that the number of ad iponecti n-posit ive 
cel l s  i s  reduced i n  d iabetes 
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F igure (20)  repre entat i\ e m icrograph sho\\ ing 
gl ucagon po i t ive cel l (Green) and au iponect in  
po i t i \ e  ce l l  ( Red) i n  pancreas i lets of d iabet ic 
treated W i  tar rat . 
- G l ucagon ( lone) 
d i ponect i n  ( Alone) 
- lerged 
ote that there i co-loca l i zation of au i ponect in 
\\ i th g l ucagon in  is let of treated rat 
iagnification : X 200 
5 5  
F igure (2 1 )  representat ive m icrographs sho\\ ing 
g lucagon po i t ive ce l l  (Green )  and ad i ponect in  
pos i t i v e  ce l l  ( Red) i n  pancreas i s lets of nonnal 
Wi  star rats treated \\ i th ad i ponect i n .  
A- G l ucagon (A lone) 
8- Ad iponect i n  (A lone) 
X 200 
I I I . 1 .c. Adi ponectin a n d  omatostat in 
d i ponect i n  doe not co- loca l ize \\ ith omatostat i n  in pancreat ic is let ce l l  of GK rats 
( F igure 22 ) .  Treatment of  G K  rats \\ i th ad i ponect i n  reduced the number of somatostat i n  
pos i t i \ e ce l l  i n  the  i l et of Langerhans ( F igure 2 3 ). I n  normal Wistar rats, adm in istrat ion of  
ad i ponect i n  i ncrea ed the  expres ion  of ad iponect i n  and reduced the t i s  ue e pre ion  of  
ornato tat i n  ( F igure 2 .. L 2 5 ). Treatment of d iabet ic W i  tar rats restored the expression of 
ad i ponect i n  ( F igure 26). Man) cel ls  in the is lets of d iabet ic Wistar rats contain both 
adi ponect i n  and somato tat in  ( F igure 27 ) .  
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representat ive micrographs 
omato tat in  posit ive cel l (Green )  
ad i ponect i n  pos i t i \ e ce l l  ( Red ) In  
pancreas i slets of normal GK rats. 
- omatostat i n  (A lone) 
lone) 
COo Merged 
*Note that No evidence of co- loca l ization 
between somato tat in  and ad iponect i n  
Magnificatio n :  X 200 
5 7  
F igure (23 ) representat ive micrographs sho\\ ing 
omatostat i n  pos i t ive cel l (Green ) and 
ad i ponect in po i t i ve ce l l  ( Red ) in pancreas is lets 
o f G K-treated rats .  
A - omato tat i n  ( Alone) 
8- Ad iponect in  ( Alone) 
* ote that the number of somato tat in -pos i t ive 
cel l s  has decreased in  adi ponectin-treated rats. 
Magnificatio n :  X 200 
5 8  
F igure (2-+)  representati \ e m icrographs 
ho\ . : 11g omatostat i n  posith e ce l l  (Green) 
and ad i ponect i n  pos i t ive cel l ( Red ) i n  
pancrea i s lets of normal-treated Wistar rats. 
- omatostat i n  ( Alone) 
8- Adiponect in ( A lone) 
C- Merged 
* ote that no co-loca l ization bet\\ een 
ad i ponect i  n and somatostati n. 
Magn ification : X 200 
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F igure (25)  representat i \ e m icrographs 
sho\\ i ng somato tat in  (Green ) and 
ad i ponecti n-pos it ive ce l l  ( Red ) in  pancrea 
i slets of normal untreated \V i tar rats.  
A- Somato tat in  ( Alone) 
8- Ad iponect i n  (A lone) 
*Note that no co-local izat ion bet\\ een 
ad iponect in  and somatostat i n .  
Magnification : X 200 
. � 
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Figure (26)  representat i \ e micrographs sho\\ ing 
somato tat i n  po i t i \ e cel l  (Green) and ad i ponect in  
pos i t ive ce l l  ( Red) i n  i s let of d iabet ic treated 
- omatostat in  ( A lone) 
8- Adiponect i n  (A lone) 
*Note that some is let cel l s  conta in  both 
ad i ponect in and somatostat i n  
Magnificatio n :  X 200 
6 1  
F igure (27 )  representat i \ e  micrographs sho\\ ing 
omato tat in  po i t ive ce l l  (Green) and 
ad i ponect in  pos i t ive cel l ( Red ) in pancreas i s lets 
of d iabet ic untreated Wistar rat . 
A- Somatostat i n  ( lone) 
8- Adiponect in (A lone) 
C- Merged 
* ot that there i s  a reduct ion in  the number  of 
ad i ponect i n-pos i t ive ce l l s .  
Magnificatio n :  X 200 
I I l . 1 .d .  Adiponectin and PP 
Adiponect i n  doe not co-loca l i ze \\ i th  PP i n  pancreat ic i s let ce l l  of GK rat ( F igure 
_ 8 )  Treatment of G K  rats \\ i th ad i ponect i n  increased the expre s ion of PP-pos i t ive cel l in  
the  i s let of  Langerhan ( F igure 29) .  In  normal Wistar rats, admin i strat ion of ad i ponect i n  
i nc rea ed  the t i s  ue  expre s ion of both ad i ponect i n  and PP  ( F igure 30 ,  3 1 ) . The number of  
adi ponect in-po i t i " e cel l i s  reduced i n  untreated d iabet ic rats ( F igure32) .  Treatment of  
d iabet i c  W i  tar rat d id  not ign i ficant ly  alter the pattern of d i stri bution of  ad iponect i n  
( F igure 3 3 )  ian), ce l l  i n  the i s lets of  d iabetic Wistar rats conta in  both ad i ponect in  and PP.  
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F igure (28)  repre entat ive m icrographs 
sho\\ i ng pancreatic poly pept ide ( PP) pos i t i \ e  
ce l l  (Green) and Adiponect i n  pos i t ive cel l 
( Red) i n  pancreas is let of normal GK rats. 
A- PP  ( A lone) 
B- d i ponect in  (A lone) 
C- Merged 
Magn ificatio n :  X 200 
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F igure (29) representat i ve m icrographs showi ng 
pancreatic polypeptide ( P P) pos it i \< e  ce l l  (Green) 
and Adiponect i n  po i t ive cel l  ( Red ) in  pancrea 
i s lets of G K treated rats. 
A- P P  (A lone) 
B- Adiponect in (A lone) 
X 200 
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Figure ( 30 )  representat ive micrographs 
ho\\ i ng PP (Green ) and Ad iponect in­
posi t ive ce l l  ( Red ) i n  pancreas is lets of 
normal Wistar rats. 
8- d iponect in  (A lone) 
lerged 
* ote that man} is let ce l l  conta in  both PP  
and ad i ponect in .  
Magn ification : X 200 
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F igure (3 1 )  representat i ve m icrographs show ing 
P P- pos i t ive ce l l  (Green ) and ad i ponect i n  
pos i t i  e ce l l  ( Red ) i n  pancreas i slets of  normal­
treated Wi tar rats .  
- PP  (A lone) 
8- Ad iponect i n  (A lone) 
C- Merged 
* ote that many is let cel l conta in  both PP  and 
ad iponect i n  
Magn ificatio n :  X 200 
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F igure ( 32 )  repre entative micrographs how ing 
pancreatic polypeptide ( P P) pos it ive ce l l  (Green) 
and ad iponect in  pos it ive cel l ( Red) in pancreas 
i lets of d iabet ic untreated Wister rat . 
A- PP  ( lone) 
B- Adi ponect in (A lone) 
X 200 
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F igure (33)  representat i \  e m icrograph sho\\ i ng 
pancreatic pol y pept ide ( PP )  posit i \ e  cel l (Green) 
and ad iponect in  pos i t ive ce l l  ( Red ) in  pancreas 
i lets of d iabetic treated Wi star rats 
A- PP ( lone) 
8- Adiponect in  ( A lone ) 
X 200 
1 1 1 . 2 .  I m m u no fl u o rescence s t u d ies of  visfa t i n  i n  pa n c reatic is lets of  v a rious 
a n i m a l  model  of  d i a bete 
I I I .2 .a .  V i  fa t in  and in u l i n  
I mmllnofl uore cence tudy show that many i let c e l l s  i n  the pancreas of  GK rats 
conta i n  vi fat i n .  Man) i s let ce l l  conta i n  both \ i sfat in as we l l as i nsul i n  ( F igure 34) .  
Treatment of GK rat s i gn i ficant ly increa es  the  number of isfat i n  and i n  u l i n-contain i ng 
ce l l  i n  panel' at ic i let ( F igure 3 5 ). I n  a i m i lar way ,  normal and v isfati n  -treated Wistar rats 
conta i n  large number of \. i fat i n-posit ive cel l s  ( F igure 36) .  Most of the v isfat in-conta in i ng 
ce l l  conta i n  i n  u l i n .  Ho\\ e\. er. \. isfati n  -po i t i  e ce l l s i n  the peri phery of pancreat ic i let don 
not conta in  in 1I l i n .  Treatment of normal Wi tar rats \\ ith \ i  fat i n  did not affect the pattern of 
di tr i but ion of \ i fat in  ( F i gure 37 ) .  The number of v isfat i n  - immunoreact i  e cel l s  decreased 
ign i fi cantl ) after the onset of d iabetes i n  W istar rats (F igure 3 8 ) Howe\ er, treatment of 
d iabet ic Wi tar \\ ith v i sfat i n  d i d  not s ign i ficant l y  alter the pattern of d i stri bution of vis fat i n ­
and i n  u l i n-po t i \ e ce l l  i n  the pancreatic i s lets ( F igure 39) .  
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F igure (34 )  repre entat i\ e micrographs 
ho\\ i ng insu l i n  pos it ive ce l l  (Green )  and 
'v i sfat i n  pos i t i ve ce l l  ( Red ) in pancreas i s lets 
of normal G K  rats. 
A- I nsu l i n  ( lone) 
8 - Visfat i n  ( A lone) 
C- Merged 
* ote that there i s  a h igh degree of 
coloca l izat ion of i nsul i n  and \ isfat i n  in is let 
cel l . 
Magnificatio n :  X 200 
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Figure ( 3 5 )  representat i \ e  m icrographs sho\\ ing 
i nsul in  pos it i  e ce l l  (Green )  and \ i sfat i n  pos i t i  e 
cel l ( Red ) in  pancreas is lets of GK rats treated 
w i th v i sfat i n .  
- I nsu l i n  (A lone) 
*Note that the number of i s let ce l ls appeared to 
ha e i ncrea ed after v isfati n treatment 
Magnificatio n :  X 200 
7 1  
F igure (36) representath e micrographs 
ho\\ i ng I nsu l i n  (Green ) and V isfati n ­
posi t ive ce l l  ( Red) i n  pancreas is lets of 
onnal W istar rats .  
- I nsul i n ( A lone) 
c - Merged 
* ote the h igh degree of co- local ization 
betw een i nsul i n  and v i sfat i n  (yel lo\\ ) 
Magnification : X 200 
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Figure ( 3 7 )  representat i v e  micrographs showing 
i n  u l i n  posi t ive ce l l  (Green) and i fati n  po i t i  e 
ce l l  (Red )  in  pancreas i s lets of normal -treated 
Wistar rats .  
A- I nsul i n  ( lone) 
8- Visfat i n  (A lone) 
C- Merged 
* ote the high degree of co-loca l izat ion betv, een 
i nsu l i n  and v i sfat i n  (yel lo\\ ) 
Magn ificat ion : X 200 
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F igure ( 38 )  representat ive micrographs 
ho\\ ing i nsul in pos i t ive ce l l  (Green )  and 
v isfat i n  po i t i " e ce l l  ( Red) in pancreas i s lets 
of d iabet ic un-treated Wistar rats .  
- I nsu l i n  ( lone) 
lone) 
c- Merged 
Magnificatio n :  X 200 
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Figure (39)  representat ive m icrographs howing 
i n  u l i n  posi t i ve ce l l  (Green) and \ i sfat in  posit ive 
ce l l  ( Red ) i n  pancreas i lets of d iabet ic treated 
W i  tar rat . 
A- I nsul i n  ( [one) 
B- V isfat i n  ( lone) 
C- Merged 
* ote that v i sfat i n  treatement d id not prevent 
the reduction in i nsu l i n  and v isfatin-contai ngi ng 
cel l s  
Magnificatio n :  X 200 
I I l .2 . h. Vi ra t in  and glucagon 
The pan reatic i let of GK rat conta in  large number of glucagon as \v e l l  as v isfat i n ­
po  i t i \  e ce l l  ( F i gure 40 ) .  V i sfat i n  does not co- local i ze \v i th gl ucagon i n  pancreat ic i s let of  
G K  rat . Treatment of G K  rats w i th " i  fati n  reduced the number of  gl ugacon­
i m munoreacti v e  cell and the degree of co- local izat ion of v is fat in and gl ucagon (F igure 4 1 ) . 
i fat in  i present i n  g l ucagon-conta ing cel l s  in  pancreat ic i s lets of normal Wistar rat 
( F i gure .+2 ). The pattern of co- local izat ion of v isfat i n  \\ i th gl ucagon remai ned the after 
treatment of normal Wi tar rat \\ i th " i sfat i n  ( F igure 43) .  Treatment of d iabet ic Wi  tar rats 
\\ i th  \ isfat l l1 enhanced ce l l u lar co-loca l i zat ion between v i  fat in  and glucagon ( F igure 4-.+ ) .  
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Figure (-'+0) representat ive micrograph 
ho\v i ng g lucagon po i t ive ce l l  (Green )  and 
v i sfat i n  po it ive ce l l  ( Red ) in pancrea i s lets 
of ormal G K rats. 
A- G l ucagon (A lone) 
B- V isfat i n  ( lone) 
C- Merged 
* ote that no evidence of co-local izat ion 
between gl ucagon and v i sfat i n  
Magn ificatio n :  X 200 
76 
F igure (4 1 )  representati e micrographs sho\\ i ng 
glucagon po i t i \ e ce l l  (Green) and v i sfat i n  
pos i t ive cel l ( Red) i n  pancreas i slets o f  treated 
GK rats .  
A- G l ucagon ( Alone) 
8- V isfat i n  (A lone )  
C- Merged 
* ote that a re l at ive decrease i n  g l ucagon 
coupled v" ith a re lat ive i ncrease in v i sfat i n  after 
treatment. Some endocri ne ce l l s  conta in  both 
gl ucagon and \ isfat in .  
Magn ification :  X 200 
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Figure (42 ) representat ive micrographs 
show ing g lucagon po i t ive ce l l  (Green ) and 
v isfat i n  pos i t i v e ce l l  ( Red ) in  pancreas i l ets 
of normal Wi tar rats. 
A- G lucagon (Alone) 
8- V isfati n ( lone) 
C- Merged 
*Note that some i let cel l s  located i n  the 
peri phery contai n  both g lucagon and v isfat i n .  
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Figure ( .. 1-3 )  representati ve micrographs shO\\< ing 
g lucagon posit ive ce l l  (Green) and 'v i fat i n  
pos i t ive ce l l  ( Red) i n  pancreas is lets of normal ­
treated W istar rats .  
- G lucagon ( A lone) 
B- V i  fati n  (A lone) 
C- Merged 
* ote that some is let cel l located i n  the 
peri phery conta i n  both gl ucagon and \ isfat in .  
M agnificatio n :  X 200 
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F igure (..J.4 ) representat ive micrographs shov" i ng 
g l ucagon posit ive ce l l  (Green)  and v isfat i n  
po i t ive ce l l  ( Red ) in  pancreas is lets o f  d iabetic 
treated Wi  star rats. 
- G l ucagon ( Alone) 
Magn ificatio n :  X 200 
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F igure (-+5 ) representati e m icrograph s l1o\\ ing 
g l ucagon pos i t i  e ce l l  (Green ) and v i sfati n 
pos i t i ve ce l l  ( Red ) i n  pancreas is lets of d iabet ic 
un-treated Wi star rats. 
- G l ucagon (A lone) 
* ote that the number of \ isfat i n  -po i t i ve  cel l s  
i s  reduced in  d iabete 
Magnificatio n :  X 200 
I I I .2 .c. Vi ra t in  and omato tatin 
i fat in  do not co-local ize \\ i th omato tat in  i n  pancreat ic is let ce l l  of GK rats 
( F igure 46 ) .  Treatment of G K rat \\ ith v i sfati n d id not a l ter the pattern of d i stribution of 
" i  rat i n  and omato tat in  i n  the is let of Langerhans (F igure 47) .  ormal and treated Wi tar 
rat hav e a i m i lar pattern oh i fat in - somatostat i n  re lation ( F igure 48 ,  49) .  Treatment of 
d iabet ic VI, i tar rats d id  not s ign i ficant l)- restored the expres ion of v i s  fat i n  and reduced that 
of omato tat in .  orne ce l l  in the i let of d iabetic W i star rats conta in  both v isfati n  and 
somato tat i n (F igure 50,5 t ). 
8 1  
Figure (46) representat ive micrographs 
sho\ i ng Somatostat in  posit ive ce l l  (Green) 
and V isfat in posit i \ e ce l l  ( Red ) in  pancreas 
i lets of normal GK rats. 
A- Somatostat i n  ( Alone ) 
*Note that some cel l s  conta in both 
omatostat i n  and v isfat in ce l l .  
Magn ificatio n :  X 200 
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F igure (47) representat i ve micrographs showing 
somato tat in  pos i t ive ce l l  (Green) and v isFat i n  
pos i t ive ce l l  ( Red ) i n  pancreas i lets of  treated 
G K  rats. 
A- omato tat i n  ( lone) 
8- Vi Fat i n  (A lone) 
conta in  both somato tat i n  and 
X 200 
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F igure (48 )  representat i ve micrographs 
show ing omatostat i n- (Green )  and V isfat i n­
pos i t ive ce l l  ( Red) i n  pancrea is let of 
normal Wistar rats. 
A- omatostat i n  (A lone) 
8- Visfat i n  (A lone) 
ote that no co- local izat ion bet\\ een \ isfat i n  
and omatostat i n. 
Magn ificatio n :  X 200 
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Figure (49)  representat i ve micrograph shO\\ ing 
somato tat in  po i t ive ce l l  (Green) and i fati n  
po i t i \ e ce l l  ( Red ) i n  pancreas is lets o f  normal­
treated Wistar rats .  
- omato tat in  ( Alone) 
B- V i  fat i n  (A lone )  
C- Merged 
* ote that no co- loca l ization bet\\een v isfat i n  
and omatostat in .  
M agnificatio n :  X 200 
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F igure ( 50 )  representative micrographs sho\\ i ng 
omato tat i n  pos i t ive ce l l  (Green) and V isfat i n  
pos i t i  e cel l ( Red ) i n  pancreas is lets of  d iabet ic 
un-treated Wi  tar rats. 
A- Somatostat i n  (A lone) 
8- V isfat i n  (A lone) 
C- Merged 
Magn ificatio n :  X 200 
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Figure (5 1 )  representat ive micrographs show ing 
somatostat in  pos it ive ce l l  (Green )  and v isfat i n  
po it i \ e ce l l  ( Red ) in  pancrea is lets of  d iabetic 
treated Wi star rats. 
A- omatostat i n  ( lone) 
8- Visfat i n  ( Alone) 
* ote that treatment v" ith v i sfat i n  reduced the 
number of omatostat in-po it ive ce l l s  
Magn ification : X 200 
1 I 1 .2 .d .  V i  fa t in and PP 
The i l e t  of G K  rat conta i n  large numbers of PP cel l . 0 ev idence of co-
local izat ion bet\\ een \ i fati n  and PP in  normal untreated GK rats ( F igure 52) .  Ho\\e  er, 
\ i fat in  co- loca l i zed \\ i th  PP in pancreat ic i let cel l of G K  rats treated \\ ith v isfat i n  ( F igure 
5 3 ). I n  n rmal W i  tar rat , adm i n i  trat ion of v isfati n decreased the t issue expres ion of 
\ i sfat i n .  orne ce l l  i n  i let peripher) contai n  both isfati n and PP  ( F igure 54, 55 ) .  
The number of i fat i n-posi t ive cel l i s  reduced i n  untreated d iabet ic rats ( F igure 56) .  
Ho\\ e\ er. treatment of d i abet i c  Wistar rats. increased t i ssue express ion of both v isfat i n  and 
PP .  l an) ce l l  in the is lets of d iabet ic W istar rat conta in  both isfat i n  and PP ( F igure 5 7) .  
F igure ( 5 2 )  representati e micrograph 
sho\\ ing pancreatic polypeptide 
posi t ive ce l l  (Green) and v isfat in  
po i t ive  ce l l  ( Red ) in  pancrea i lets of 
ormal GK rats . 
A- PP  (A lone) 
B- V i  fat in  (A lone ) 
C- Merged 
ote that the i s lets 0 f normal G K rats 
conta in  large quanti t i t ies of v i s  fat i n  and 
PP 'W i th no evidence of co-loca l izat ion. 
Magn ification :  X 200 
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F igure ( 5 3 )  representative m icrographs sho" ing 
pancreat ic pol y pept ide C P P) posi t ive cel l (Green) 
and Visfati n po it i v e  ce l l  ( Red ) in  pancreas is lets 
of G K- rats treated 'v i th v isfat in .  
A- PP  ( lone) 
8- Visfat i n  ( lone) 
* ote that the number of PP-posit ive ce l ls i s  
h igh .  Many i s let c e l l s  conta in  both PP and 
v isfat i n  
X 200 
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F igure (54)  representat i ve m icrographs 
sho\\ ing PP (Green) and v i sfat i n- po iti e cel l 
( Red ) i n  pancreas is lets of normal Wi  tar rat . 
A- PP  (A lone) 
8- Vi fat i n  ( Alone) 
C- Merged 
* ote that ce l l s  i n  the peri pher) of the is lets 
conta in  both \ isfat i n  and PP  
Magnification : X 200 
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F igure ( 5 5 )  representat ive micrographs sho\\ i ng 
PP  ce l l  (Green )  and visfat in- pos i t ive cel l ( Red ) 
i n  pancrea i s lets  of normal Wistar rats treated 
\" i th v isfati n 
- PP  ( lone) 
*Note that ce l ls in the periphel"} of the is lets 
contai n  both isfat i n  and PP  
9 1  
F igure ( 5 6 )  representat ive micrographs sho\ i ng 
pancreat ic polypept ide C P P) posit i \ e cel l (Green )  
and V i  fat i n  pos i t ive ce l l  ( Red) i n  pancrea i s lets 
of d iabetic un-treated Wistar rats .  
A- PP  ( lone) 
B- V i  tuti n  ( lone) 
C- Merged 
* ote that the number of v i  tat in-po i t i  e ce l ls 
decrea ed in  d iabetic rat . 
Magnification : X 200 
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F igure ( 5 7 )  representat ive m icrographs sho\'v i ng 
pancreat ic pol y peptide ( PP )  pos it ive cel l (Green) 
and V isfati n pos i t ive ce l l  ( Red) in  pancreas i s lets 
of d i abet ic treated Wistar rats. 
A- PP ( A lone) 
8- V isfat i n  (A lone) 
*Note that many i let cel l conta in  both v i sfat i n  
Magn ification : X 200 
I 1 1 .3 .  I m m u no fl uo resce n ce s t u d ies of  ad iponecti n  a n d  visfat in  i n  
u bc u ta n eo u s  a n d  vi  c e r a I  fa t 
I n  order to atte t \\ hether ad i ponect i n  and v i  fat in  are loca l i zed to fat t issue. \\ e 
stained for ad i pone t i n  and \ i sfat i n  i n  subcutaneou fat .  The expression of ad i ponect in  i s  
tronge t i n  the  subcutaenou fat of d iabet ic rat compared to non-diabet ic normal Wistar rats 
( F igure 5 8 ). I n  a i m i lar manner. the expression of isfat in wa strongest i n  the subcutaneous 
fat of d iabet i c  Wi tar and G K  rat ( F igure 5 9 ). 
F igure ( 5 8 )  representat i \. e m icrographs showing 
ad i ponect i n  pos i t ive ad i poc) tes i n  the 
A: onnal  G K  rat . 
B :  ormal W i  star rats 
C :  D iabet i c  \\ i star rat . 
* ote that the express ion of ad i ponect i n  i s  
tronger i n  d iabet i c  Wi  tar rat . 
�lagn ifica tio n :  X200 
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F igure C9) representat i v e  m icrographs sho\\ ing 
v i  fat i n  po i t ive adi pocy tes i n  the subcutaneou 
fat of: 
A :  Normal  G K  rats 
B :  orma l  W i star rat 
C :  D iabet ic W i star rats. 
* ote that the expre s ion of " i fat in  i s  stronger 
in d iabet i c  (A. C )  rats .  
Magn ificatio n :  X 200 
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Adiponecti n - immunopo i t i \ e ad i pocyte I n  the epid idy mal fat of untreated GK.  
n rmal v.. i tar and d iabet ic Wi  tar i n  figure 60 .  The  pattern and intens ity of ad i ponect i n  
expre i on  app  a r  t o  be  i m i l ar i n  a l l  groups of  animal te ted. [ n  contrast. the e pres ion of  
\ i sfat i n  appear to  b stronge t i n  the epid idymal fat of  d iabet ic Wistar rats (F igure 6 1 ) . 
F igure (60)  representat i ve m icrograph sho\\ i ng 
adi ponecti n-po it i \ e  ad i pocyte i n  the 
epidid) mal  fat of: 
A :  ormal G K  rats. 
B :  ormal W i star rats 
C: Diabet ic W i star rats .  
�lagn ificatio n :  X200 
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F igure (6 1 )  repre entat i \ e m i c rograph howing 
\ i fatin -po i t i \ e adipoc)te in the epid id) mal fat 
of 
A: o rma l  GK rat 
B :  j ormal \V i  tar rats 
C :  D iabetic Wi tar rat . 
* 'ote that \ j fat i n  appears to be more expressed 
i n  \ i cera l fat of d i abet ic W i star rats. 
Magnifica tion : X200 
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I V. Effect of ad iponect in  a n d  v isfat in  o n  is let m o rpho logy 
Figure (62 . B, 6 .... . B, 64. B )  ho\\ that the i s let o f  G K ,  normal and d iabet ic W i  star rats 
treated \\ i th  ad i pon ct in  are larger than those of control F igures (62 .A 63 .A, 64 .A) 
I n  a i m i lar trend, \ i fat i n  i ncrea ed the s ize of pancreat ic i s lets i n  GK, normal and d iabet ic 
\\ i tar rat' after  tr atment for 1 4  \\ eek F igures (65 .B ,  66.8 .  67 . 8 )  
F igure (62 ) repre entat i \ e  m ic rographs ho\\ i ng i s lets i n :  
A- ormal G K  rats 
B- G K  rat treated \\ i th adiponect i n  
* ote that a larae increase i n  the ize of i let i n  treated rats \ ersus contro l .  o 
Magn ificatio n :  X -400 
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F igure (6"' ) representat ive m ic rographs sho\\ ing i s lets i n :  
orIllal Wi  tar rat 
B - omlal Wi  tar rat t reated \\ i t h  ad iponect in 
* 'ote an i ncrea e i n  the s ize of  i s let in treated rats v ersu contro l .  
Magn ificatio n :  X '"'00 
F igure (64 ) representat ive m ic rographs sho\v ing is lets of: 
- Diabetic W i star rat 
B- D iabetic W istar treated with Adiponect in 
* ote that the large i let  i n  the d iabetic treated rat sho\\ 5 a con plCUOU recovel) . 
M a g n i fication : X "'00 
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Figure ( 65 )  repre entat i \ e  m icrograph 
onnal  K rat · 
8- K treated \\ i th  \ i fat in  
'" ote a · l11al l  i ncrea e i n  the s ize o f  is let o f  treated rat . 
Magn ification : X -'00 
F igure (66)  representat i \ e m icrograph 
\- 'ormal \\ i tar rat 
8- o rmal  Vv i tar rat treated \\ i th " i  Fat in  
* .  ote that the ize o f  i let i n  treated rat i s  larger compared to contro l .  
M agn ificat io n :  X -'00 
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Figure (67 )  repre entat i \  e m icrograph 
-\- Diabet ic  Wi -tar rat 
B- Diabetic W i  tar treated \\ i th " i'tatin  
fhere i a sma l l  increase i n  the  size of is let i n  treat d group compared to contro l .  
M agn ification : X ..tOO 
1 00 
V. E ffect of ad iponect in  a n d  visfati n on the  u lt ra structu re of 
p a n c reatic beta ce l l s  
I let morpholog} \\ a ign i ficant l }  improved i n  GK ,  normal  and d iabet ic Wi star rats 
treated \\ i th e i ther ad i ponect i n  or v i  fat i n . F igures (68-73 ) 
A B 
Figure (68 ) representat i v e  m icrographs sho\\ i ng u l tra tructure of pancreat ic  beta 
ce l l  . 
A .  Pancreat ic beta ce l l s  i n  GK control 
B. Pancreat ic beta cel l s  in G K  treated \ ith ad iponect in .  
* ote the large i ncrease in  pancreat ic beta ce l l  granule .  
Ma g ni ficatio n :  X U, 5000 
1 0 1  
A B 
F igure (69)  r p re entat i \ e  m icrograph sho\\ ing u l tra 'tructure of pancreat ic beta 
. Pancreat i c  beta ce l l  i n  G K  control 
B. Pancreat i beta cel l ' l n  K treated \\ i th \ i  fat i n .  
* ote the large increa e i n  pancreatic beta ce l l  granule.  
M agn ification :  X U, 5000 
1 02 
A B 
Figure ( 70 )  repre entat i \ e m ic rograph sho\\ ing u l tra tructure of pancreat ic beta 
ce l l . 
A . Pancreat ic beta cel l s  i n  normal W i  tar 
B .  Pancreat ic  beta cel ls  in normal Wi star treated \\ i th ad i ponect in .  
* ote the large i ncrease i n  pancreat ic beta cel l granule 
M a g n i fication :  X U, 5000 
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A B 
Figure ( 7 1 )  representat i \ e m ic rograph sho\\ ing u l tra structure of pancreat ic beta 
ce l l . 
A .  Pancreatic beta ce l l  i n  normal W i star 
B .  Pancreat i c  beta cel l s  in normal W istar treated \\ i th vi fat in .  
* ote a large i ncrease i n  pancreat ic beta ce l l  granule 
M agn i fication :  X U, 5000 
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A B 
Figure ( 72 )  repre entat ive IT1 icrographs sho\v ing u l tra tructure of pancreatic beta 
cel l s  . 
. Pancreat ic beta ce l ls i n  untreated d iabet ic 
B .  Pancreat ic beta ce l l  in  Ad i ponect in  -treated Wistar rats . 
* 1  ote that a large increase i n  pancreatic  beta ce l l  granule of treated rats 
�lagn i ficatio n :  X H, 5000 
1 05 
A B 
F igure ( 73 )  repre ntat i \ e  m icrograph 'ho\\ ing u l t ra tructure of pancreat ic  beta 
cel l . 
. Pan reat ic beta ce l l  i n  untreated d iabet ic 
B .  Pancreat i c  beta cel l s  in i fat in-treated Wi tar rat . 
ote that a large i ncrea�e i n  pancreat ic  beta ce l l  granule of treated rats. 
:\lagn ification :  X U, 5000 
1 06 
V I .  I m m u noe lectron m I c ro copy of ad ipo nectin a n d  vi fat in  i n  
p a n c reatic i let cel l 
\d iponcct in  anti \- i fal i n  \\- ere ob er\ ed i n  'ecretor) granules of pancreat ic is let ce l l  
i n  GI\. \-\ c l l  a�  V\ i tar  rat ' .  \,Ian) seer tor) granule conta i n  both ad i ponect in  and in  u l i n  or 
\- i :rat i n  and in u l i n . ome ad i ponect in  and \. i fat i n-po t i \ e  go ld part ic le \-\-ere a l  0 ob en ed 
on the rough endopla m i c  ret icu lum.  ( F igure 74-75 ) 
A B 
F igure ( 74 )  repre entat i \- e  subce l l u lar loca l izat ion o f ad i ponect in and i n  u l i n  ( 
and \- i tat i n  and i n  u l i n  i n  pancreat ic i let cel l of G K  rat ( B ) 
* lote that i n  u l i n  ( 1 0 nm gold part ic les)  and \- i tat i n  (20 nm go ld part ic le ) co­
local ize \\ ith ( ) ad i ponect i n  ( 20 nm go ld part i c le )and ( B )  \- i s tat in  
� l agn ificatio n :  X 35, 000. 
1 07 
A B 
Figure ( 7 5 ) repre entat i "  e subce l l u lar local izat ion of ad i ponect in  and i n  u l  i n  (A)  
and 'v i  fat i n  and i n  u l i n  i n  pancreat ic is let cel l of normal  W istar rats. ( 8 )  
* ote that insu l i n  ( 1 0  n m  gold part i c les) and v i sfat i n  ( 2 0  n m  go ld  part ic le ) 
co- loca l i ze \\ i th  ad i ponect i n  (20 nm gold part ic les)  ( A )  and ( 8 )  v isfat in .  
M agn ification : X 35 ,  000. 
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VII. Pia  rna I n  u l i n  a n d  glucago n  level of G K, n o rm a l  a n d  
Dia betic W i  ta r rat after a d i ponect i n  a n d  v isfat in  treatment 
onnal \\ i star rat treated \\ i th 'v i  rat in  ho\\ ed a s ign i ficant(p <0.05 ) decrea e i n  
p ia. ma i n  'u l i n  le\  e l  compared to ad i ponect i n  treated and untreated contro l .  I n  contra t. the 
i n u l i n  le\ e l  of  d iabet ic W i  tar rat treated \\ i th e i ther adi ponect i n  or \ i fat in  i ncreased 
s ign i ficant l )  ( p  0.0 - ). I n  add i t ion. ad i ponect i n  i ncreased le\ e l  \\ h i le \ i  fat i n  decrea ed 
p lasma in u l i n  i n  G K  rat ( F igure 76-78). 
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Figure ( 76 )  sho\\ p ia  °ma i nsu l i n  le\ e l  i n  normal \\ i tar rat treated \\ i th either 
ad i ponect i n  or \ i sfat i n .  onnal Wi tar rat treated \\ i th \ i - rat i n  sho\\ s ign i fi cant (p  <0.05 ) 
decrea e i n  p ia  ma i nsul i n  le\ e l .  
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WR-Diabetic WR-Diabetic-Ad i ponectin WR-Diabetic-Visfatin 
Figure ( 7 7 )  sho\\ s p ia  ma in u l i n  levels in d iabet ic Wistar rat treated \\ ith e ither 
ad i ponect i n  or 'v i sfat i n .  D iabet ic Wistar rats treated \\ i th e i ther adiponecti n or 'v isfat i n  ho\\ 
s ign i fi cant ( p  <0.005 ) :  p < 0 .0005 ) increa e i n  p lasma i nsul i n  leve l .  
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G K  G K-Adiponectin G K-Visfati n  
Figure ( 7 8 )  shows p lasma insu l i n  l evels i n  G K  rats treated w ith e i ther adi ponecti n or 
\- isfat i n .  G K  rats treated \\ i th adi ponect in  shov .. ed a s ign ificant i ncrease in  plasma i nsu l i n  
le \ e l  \\ h i l e  those treated \\- i th v i  fat in  have s ign i ficant ( p  <0.05 ) decrease in  plasma 
i nsul i n  leve l .  
1 1 0 
r h plasma level or g lucagon incr a ed � igni ficantl) i n  normal Wi  tar rat treated 
\\ i th  \ i fat in  compared to control . The plasma lev e l  of gl ucagon in d iab t ic Vv i tar rat \\ a' 
not al tered after treatment \\ i th t: i ther ad iponect in  or v i  fat i n .  I n  contra 1 .  the pia rna le\ e l  of 
g lucagon de rea 'ed sharpl )  in GK rat treated \\ ith ad i ponect in (F igure 79-8 1 )  
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F igure ( 79 )  ho\\ pia ma g lucagon lev e l  i n  normal Vv i tar rat� treated \\ i th e i ther 
ad i ponect i n  or v i sfati n .  orrnal Wistar rat treated \\ ith v i  fat in  ho\\ s ign ificant (p <0.05 ) 
increa e i n  p ia  rna g lucagon lev e l .  
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Figure ( 80 )  hO\vs p Ia m a  g lucagon level  i n  d iabet i c  Wistar rats treated \\ i th e i ther 
ad i ponect in  or v i sfat in .  There i no s ign ificant d i fference between the 3 groups. 
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G K  G K-Adiponect in  GK-Visfatin 
Figure ( 8 1 )  sho\\ s p lasma g l ucagon level in G K  rats treated with e i ther ad i ponect i n  or 
\ i fat i n. 
ote that G K  Wi star rats treated \\ ith ad iponect in  show s igni ficant (p <0.005)  decrease in 
p lasma g l ucagon leve l .  
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VIII. I n v i tro effect of a d i po p n ect in  a n d  v isfat in  on in  u l i n  and  
g lu cagon relea e 
V I I I .  I .  E ffect o f  a d i ponect i n  o r  v i  fa t i n  on  i n s u l i n  re lease 
V I I L t .  a. E ffect of  a d i pon ectin on  in u l i n  relea e 
\d iponect in  i nh i b i ted i n  u l i n  from the pnncren or Vv i star rats at  1 0- 1 2 I .  0 
ign i ficant effect of ad i ponect i n  \\ a ob en,ed in  GK rat ( F i gure 82-85 ) 
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Figure ( 82 )  ho\\ the effect of  d i fferent concentrat ion 
GK rat 's  pancreatic t is  ue. 
1 0"' (M) 
d iponect in  on in u l i n  re lea e of 
ote that ad i p  nect i n  cau ed a ' I i ght but not ign i ficant i ncrease i n  in u l i n  relea'e at 1 0- 1 -;  1 
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Mech a nism of Adiponect in - i nd uced insu l in  re lease from the pancreas of G K  
Rats 
Adlp 10 '2  (M) Adlp 1 0. ,2 (M)+ 
1 0. 6 (M) Atrop 
Adlp 1 0 1� (M)+ 
1 0 6 (M) YOh 
. 
Adlp 1 0  12 (M)+ 
1 0 6 (M) 011  
Adlp 1 0 '1 (M)+ 
1 0. 6 (M) Prop 
: igure ( 83 )  'ho\\ ' insu l i n  re lea 'e from th pancreas of normal GK rats after i ncubation \\ i th d i fferent 
ceptor antagon i  t . 
ote that neith r. atrop ine ( atrop). ) oh imb ine ( Yoh) ,  nor proprano lol ( prop )  affect ad i ponect i n ­
ndu ed  i nh ib i t ion of i n  ' u l i n  re i a e .  O i l t iazem ( O i l )  cau,>ed a l i ght but not igni ficant decrease in  
n u l i n  rdease.  
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Figure ( 8  .. l ) ho\\ the effect of d i fferent concentrat ion ' of ad i ponect in  on i n  u l i n  re lease 
from the pancrea of normal and d iabet ic  \\ i star rab. *l\J te that ad iponecti n s igni ficant l )  
i nh i bi ted i n u l i n  re lea e from the  pancrea of both normal and d iabet ic rab a t  1 0- 1 2  I .  
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Mechan ism of Ad lponectln" lnduced Insul in release from the pancreas of normal .. 
WR & dlabetlc .. WR 
Normal Wista r 
Dia betic Wistar 
* 
* 
Adlp 1 0'u (M)  Adlp 1 0" £ (M)+ Adlp 1 0" £ (M)+ Adlp 1 0" £ (M)+ Adlp 10 '£ (M)+ 
10 6 (M) Atrop 1 0. 6 (M) Yoh 1 0  6 (M) 011  1 0' 6 (M) Prop 
Figure ( 8 - ) ho\\ i n  u l i n  re lea e from the pancreas of normal & d iabet ic  .. W i  tar rat- after 
i ncubat ion of t i  ue ' \\ i th d i fferent receptor antagoni t . * ote that i ncubat ion \\ i th ei ther 
atropine ( trop) .  ) oh imb i ne ( Yoh). or d i l t i aLem ( Di l )  caused large increa e in i n u l i n  
realease from the pancrea of d iabet ic rat . 
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V I I I . 1 . b. E ffect of y i  fa t in  on  in  u l i n  release 
i fat i n  i nh ib i ted in u l i n  re lea e from pancreat ic t i ssue fragments of Wistar rats at a l l  
concentrat ion espec ia l l .  i n  d iabetic Wi  tar  rats. V i sfati n  did not cause any signi ficant 
change i n  i n  u l i n  re lease from the pancreas ofGK rats. ( F igure 86-89) 
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Figure ( 86 )  show the effect of d ifferent concentrat ions of vis fat in on i nsul in  release from 
the pancreas of G K  rats. 
* ote that v i sfat i n  d id not affect insu l i n  re lease at the concentrat ions u ed. 
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Mechan ism of Vlsfatin- Induced Insul in release from the pancreas of GK Rats 
VIS 1 0·� 
* 
VIS 1 0·� (M)+ 
1 0· 6 (M) Atrop 
* *  
VIS 1 0'� (M)+ 
1 0· 6 (M) Yoh 
VIS 10·\1 (M)+ 
1 0. 6  (M) 011  
VIS 10·\1 (M)+ 
1 0· 6 (M) Prop 
Figure ( 8 7 )  sho\\ i n su l i n  re lease from the pancreas of normal GK rats after incubat ion \\ ith 
d i fferent receptor antagon i  ts. * ote that nei ther. d i l t iazem ( D i l )  nor propranolol  ( prop )  
affects 'v i fat in- i nduced i nsul i n  re lease . Ho\\ ever, atrop ine (atrop) and ) oh imb ine ( Yoh), 
caused ign ificant decrea es i n  i n  u l i n  release. 
* ( p< O.05 ) ,* *( p<O.005 ) 
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Figure ( 88 )  ho\\ the effect of d i fferent concentrations of v i s  fat in on i nsul i n  release from 
the pancrea of normal and d iabet ic Wistar rats. * Note that \ isfat in inhibits (p�O.05) insulin 
re lea e from the panc reas of normal Wistar rats. 
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Mechanism of vlsfatln- induced I nsul in release from the pancreas of normal-WR 
& dlabetlc-WR 
Vis 1 0'� (M)+ 
1 0' 6 (M) Atrop 
VIS 1 O'� (M)+ 
1 0· 6 (M) Yoh 
VIS l O'Y (M)+ 
1 0, 6 (M) 011 
• Normal Wistar 
• Diabetic Wistar 
VIS 1 O'� (M)+ 
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Figure ( 89 )  sho\\ s i nsu l i n  re lease from the pancrea of normal and diabet ic Wi tar rats after 
incubat ion of t i ssue \ ith v isfat i n  and d i fferent receptor antagonists. 
* ote that i ncubat ion \V i th  d i l t iazem ( O i l )  caused large i ncreases in insu l i n  re lease from the 
pancreas of  both normal  and d iabet ic rats. 
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V I I I . 2 .  E ffect of a d i po nectin o r  visfa t i n  on  g l u ca gon release 
VI I I .2 .a.  Effect of ad iponectin on  glucagon relea e 
Adt ponect i n  i nh ib i ted gl ucagon re lea e from the pancreas of normal Wistar rats but 
had no igni  ficant effect on gl ucagon secret ion from GK rats. The effect of adi ponect in on 
glu agone ecret ion \\ a not mod i fied b) e i ther cho l i nergic or adrenergic receptor 
antagon i  t . ( F igure 90-93)  
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Figure (90)  ho\\ s the effect  of d i  fferent concentrat ions of ad i ponect i n  on gl ucagon re lease 
from normal  G K pancreas. 
* ote that there i s  a s l i ght but not a s igni ficant decrease in g lucagon re lease from the 
pancrea o f G K  rats after treatment \\ i th  ad i popnect in .  
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Mechan ism of Ad lponectin-tnduced Glucagon release from the pancreas of 
normal-GK rats 
Adlp 1 0.1< (M) Adlp 10 .1 .1  (M)+ 
1 0· 6 (M) Atrop 
Adlp 1 0. 1.1 (M)+ 
1 0. 6 (M) Yoh 
Adlp 1 0.1.1 (M)+ 
1 0. 6 (M) 011 
Adlp 1 0·1£ (M)+ 
1 0· 6 (M) Prop 
Fig u re (91 ) shows g lucagon release from the pancreas of normal  GK rats after 
i ncubat ion with d ifferent receptor antagon ists. *Note that neither, atropine (atrop),  
yoh imbine (Yoh) ,  d i lt iazem (Oi l )  nor  propranolol  (prop) affects adiponectin- induced 
inh ibit ion of g lucagon release 
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Figure (92 ) shov, s the effect of d i fferent concentrat ions of adi ponect i n  on glucagon re lea e 
from the pancreas of normal and d iabet ic  Wistar rats . * Note that ad i ponect in  caused an 
increase i n  gl ucagon release from the pancrea of normal rats but inh i b i ted glucagon 
ecret ion from d iabetic  rats. 
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Mechanism of Adlponectln-Induced Glucagon release from the pancreas of 
normal-WR & dlabetlc-WR 
Adlp 1 0-'< (M)+ 
1 0- 6  (M) Atrop 
Adlp 1 0-" (M)+ 
1 0- 6 (M) Yoh 
Adlp 1 0-1 < (M)+ 
1 0- 6  (M) Oil 
• Normal Wista r 
Diabetic Wistar 
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Figure (93 ) sho\\ s g l ucagon re lea e from the pancreas of nonnal  and d iabet i c  Wistar rats 
after i ncubat ion \\ i th  d i fferent receptor antagon ists. * ote that neither, atrop ine (atrop). 
j oh imbine ( Yoh )  or propranolol (p rop) affects ad i ponect i n- i nduced inh ib i t ion of glucagon 
re lease . Ho\\e \ er, add i t ion of d i l t iazem ( D i l )  caused large i ncreases in gl ucagon release 
1 2 1  
V U I .2.h.  E ffect of v i  fa t in  o n  glucagon release 
i rat i n  't imulated gl ucagon re lea e from pancreat ic t i ssue fragments of GK rats at 
1 0-6 1 and i nh ib it at 1 0,9M .  It fai led to cause an) s ign i ficant changes in  g l ucagon release 
from the pancrea of Wi tar rats .  ( F igure 94-97) 
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F igure (94) shows the effect of d ifferent concentrations of Visfatin on g lucagon 
release from norma l  GK pancreas. 
* Note that Visfat in  shows a biphasic effect, caus ing a sig nificant decrease in 
g lucagon release at low concentration and a sign ificant increase at high 
concentrat ion .  
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Mechanism of Vlsfatln-Induced Glucagon release from the pancreas of normal­
GK rats 
Vis 1 0'� (M) VIS 1 0 �  (M)+ 
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Figure ( 9 � )  ho\\ s glucagon re lea e from the pancreas of normal GK rats after incubat ion 
\\ i th  d i fferent receptor antagon i  ts. *Note that ne ither. atropine (atrop), yoh imbine ( Yoh),  
d i l t iazem ( Di l )  nor propranolo l  ( prop)  affects v i  fat i n- i nduced inh ibi t ion of gl ucagon release 
0.18 
-
Q) ::l 0. 16 en 
Normal Wistar 
� Diabetic Wistar 
01 0.14 E 
0 
0 0.12 
..-
--
0 0.10 E 
S 
Q) 0.08 en ro Q) 0.06 Q) 
'-
c 0.04 0 01 ro (J 0.02 
.2 
c.? 
0.00 
BASAL 1 O.1f (M) 1 O �(M) 1 0"" (M) 
Visfatln 
Figure (96 ) shows the effect of d i fferent concentrat ions of v is fat in on g l ucagon re lea e from 
the pancrea of normal and d iabetic Wistar rat . V i sfat i n  bas no effect of glucagon secret ion 
in normal rats but appear to inh ib i t  g lucagon re lease from the pancreas of d iabet ic rats 
( n  = 6) .  
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Mechanism of visfatin- induced Glucagon release from the pancreas of 
normal-WR & d iabetic-WR 
VIS 1 0'Y (M) VIS 10·\1 (M)+ VIS 1 0'Y (M)+ 
1 0' 6 (M) Atroo 1 0' 6 (M) Yoh 
VIS 10'Y (M)+ 
10' 6 (M) 01 1  
• Normal Wistar 
• Diabetic Wistar 
VIS 1 0'Y (M)+ 
1 0 6 (M) Prop 
F igure (97 ) 110\\ g l ucagon re lease from the pancreas of nonnal  and d iabet ic Wistar rats 
aA:er i ncubat ion \\ i t h  d i fferent receptor antagon ists. * ote that neither, atropine (atrop), 
d i l t iazem ( D i l )  nor propranolol (p rop) affects v isfat in - induced i nhi b i t ion of glucagon release. 
Ho\\ e\ er. i ncubation \\ i th  y oh imbine ( Yoh )  and 'v isfat i n  caused a large increase in glucagon 
re lease. ( n  = 6 ) . 
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IX. Effect  of ad iponect in  a n d  visfat in  on biochemic a l  
pa ra m eters 
I X. 1 .  L iver  fu n ct ion tests 
I bum in :  F igure (98- 1 00 )  shows plasma albumi n  level in nonnal and diabet ic 
� i tar  and GK rat treated \\  i th e i ther ad iponect i n  or v isfat i n  for 1 4  \\ eeks. V isfat i n  cause 
ign i ti cant increa es ( p  < 0.05 ) in the album in level of d iabet ic Wi tar rat compared to 
adi ponect i n-treated and contro l  Wistar rats. [n contrast. adi ponect in induce large i ncrease i n  
p i a  ma a lbumi n  le\ e l  i n  G K  rats compared to  control 
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Figure ( 98 )  sho\\ the Ie el of p lasma a lbumin  in normal Wistar rats treated \\ ith e i ther 
ad i ponect i n  or \ i sfat i n .  Ne i ther isfat i n  nor ad i ponect in has effect on plasma albumin  
level .  
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Figure ( 99 )  ho\\ the level of p lasma album in  in d iabet ic Wistar rats treated \\ ith e i ther 
adi pone t i n  or \ i fat i n .  ote that Vi rat i n  i ncreased p lasma album in  le\ e l  s ignificantl) ( P  
<0.05 ) 
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Figure ( 1 00 )  shov, s the level  of p lasma a lbumin i n  G K  rat treated \\ ith e i ther ad i ponect in 
or \ i rat in .  ote that ad i ponect in caused a s ign i ficant (P < 0.05 ) increase i n  plasma 
album in  le \ e l  
1 26 
The Ie e l  of GGT \\ a not al tered in  GK and normal Wistar rats treated \\ ith either 
ad i ponect i n  or \. i fat i n .  HO\\ ever, the p lasma level of d iabet ic Wistar rat treated ad iponect i n  
increa ed  ign ifi cant l y  ( F igure 1 0  I - I 03 ) .  
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Figure ( 1 0 1 ) sho\\ the level of gamma g lut am) I tran ferase (GGT) pia rna le\. e l  i n  normal 
Wistar rat . 0 d i fference \\ as observed in the three groups. 
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Figure ( 1 02 )  shows  gammaglutamyl transferase (GGT) pia rna Ie  e l  in normal Wistar rats 
treated \\ i th  e i ther ad i ponect in  or v isfat in .  Note that W i  tar d iabet ic rats treated \\ i th 
ad i ponect in ho\\ s ign i fi cant (p < 0.05 ) increase i n  GGT pia rna level .  
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Figure ( 1 03 )  sho\\ gammagl utam) I transferase ( GGT) plasma lev el i n  GK rats treated 
\\ i th  e i ther ad i ponect i n  or v isfat in .  No d i fference \v as observ ed in the three groups 
LDH le\ e l  was ign i ficant l} ( p  < 0.05 ) reduced in d iabet ic Wistar and G K  rats treated \\ i th 
\ i fati n  ( F i gures 1 04- 1 05 ). 
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Figure ( 1 04 )  sho\\ s the l ev e l  of p lasma lact ic dehyd rogenase in normal Wi tar rats treated 
\\ i th  e i ther  ad i ponect in or \ isfat i n .  There \\ as no s ign i ficant d i fference between the 3 
groups. 
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F igure ( 1 05 )  sho\\ s the le\ e l  of p ia ma lact ic  deh) d rogenase in d iabet ic Wistar rats treated 
\\ i th  e i ther ad i ponect i n  or \ i rat in .  ote that d iabetic rats treated \\ i th \ i sfat i n  sho\\ 
ign ificant ( p  < 0.05 ) decrease in lactic dehydrogenase plasma level 
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F igure ( 1 06 )  sho\\ s the level of pia ma lact ic dehydrogenase in G K  rats treated w ith e i ther 
ad i ponect in  or  \- isfat i n .  ote that GK rats treated \\ i th vi fat in  sho\y a ign i tlcant (p < 0.05 ) 
decrea e i n  lact ic dehydrogenase plasma Ie e l .  
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A L P  level \\ a ign i ficantl) reduced i n  normal Wi  tar and GK rats treated \.\ ith e i ther 
ad i ponect i n  or  \ i  fat in .  0 s ign i ficant change \.\. as seen i n  the level of  ALP in  d iabet ic Wistar 
rat ( F i gure '  1 07- ( 09) .  I n  contra t, the e drugs fai led to cause sign ificant changes in  the AL T 
le\ e l  ( Figure 1 1 0- 1 1 2 ) .  A T level \.\ as i gn i ficant ly reduced in  normal and GK rats treated 
\\ i th ad i ponect ion ( F igure I t 3 - 1 1 5 ) .  
40 
35 
30 
25 
* 
ALP ( lUll) 20 I * *  15 10 
5 
0 
WR-Normal WR-Normal-Adiponectin WR-Normal-Visfatin 
Figure ( 1 07 )  sho\\ s the level of plasma a lkal i ne phosphatase in normal Wistar rats treated 
\\ i th  e i ther ad i ponect i n  or vi fat in .  Note that both ad i ponect in and v i  fat in  igni ficant l )  ( p  < 
0.05 ) decreased the p lasma alkal i ne phosphatase lev e l  
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Figure ( 1 08 )  ho\\ the Ie el of plasma alkal i ne pho phatase i n  d iabet ic Wistar rats treated 
" ith e i ther ad i ponect i n  or \I i  fat i n .  ote that LP  i lo\\ er i n  the treated group. 
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Figure ( 1 09 )  ho\\ s the l evel of p lasma alkal i ne phosphatase in GK rats treated " ith ei ther 
adi ponect i n  or \ i fat i n .  ote that e i ther ad i ponect in  or vi fat in  s igni ficant l )  (p < 0.05 ) 
caused a decrease i n  p lasma a lka l i ne phosphatase leve l .  
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Figure ( J  J 0) shows the lev e l  of plasma a lan i ne am inotransfera e in normal Wistar rats 
treated \\ i th  e i ther ad i ponect i n  or \ isfat i n .  0 s ign i ficant d i fference \'va een i n  the three 
group . 
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Figure ( I I I )  sho\\l S the Ie e l  of plasma a lan ine am inotransferase in  d iabetic Wistar rats 
treated \\ i th e i ther ad i ponect i n  or \ i sfat i n .  There \V as a s l i ght but not igni ficant decrease in  
AL T le\ e l  after treatment \\l ith v isfat i n .  
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Figure ( 1 1 2 ) sho\\ s the level of p lasma a lan ine ami notransferase in  GK rats treated \\ i th 
e ither ad i ponect i n  or \ i fati n. 0 ign ificant d i fference \\ as seen i n  the three groups. 
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Figure ( I  1 3 ) sho\'v s a partate am i notransferase p ia  ma level i n  normal Wi tar rats treated 
\\ i th e i ther ad i ponect i n  or v i sfat i n .  ote that ad iponect in-treated rats d i splayed igni ficant 
( p  < 0 .05 ) reduct ion in p lasma A T ie e l .  
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Figure ( 1 1 4) sho\\ a partate am inotransfera e p lasma level in  d iabet ic Wistar rats treated 
\\ ith e i ther ad i ponect in  or \ i  fat in .  ote that rats treated \\ ith ei ther ad iponect i n  or vi fat i n  
sho\\ ed a l ight but not s ign i ficant decrease i n  p lasma AST leve l .  
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Figure ( 1 1 5 ) sho\\ s aspartate am i notransfera e p lasma level i n  GK rat treated \\ i th e i ther 
ad iponect in  or v isfati n.  ote that ad iponect i n-treated rats d i  pl ayed s ign i ficant (p < 0.05 ) 
reduct ion i n  p ia  rna A T leve l .  
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I X . 2 .  L i p ids  
The p ia rna lev e l  of trig l ) cerides \\ a igni ficant ly  lower i n  d iabet ic Wistar rats 
treated \\ i th ad i ponect i n  compared to contro ls  but increased i n  normal Wistar rats treated 
\\ i th  \ i sfat i n  ( F igures 1 1 9- 1 2 1 ). Total chole teral decreased in normal Wistar rats treated \\ i th 
ad i ponect i n  but increased i n  d iabet ic Wistar treated vv i th e i ther ad iponect in or v isfat i n  
( F igure 1 1 6- 1 1 8). 
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Figure ( 1 1 6 ) ho\\ chole terol  p lasma Ie els in normal Wistar rats treated \\ i th either 
ad i ponect i n  or  \ i fati n .  ote that ad i ponect in- treated rats showed s igni ficant (p < 0.05 ) 
reduct ion i n  p lasma cholesterol le\ e l .  
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Figure ( 1 1 7) hO\\ s cho lesterol p lasma leve l  i n  d iabetic rats treated \\ ith e i ther ad i ponecti n  
o r  v i  fat i n .  ote that ad i ponect in- and v i sfat i n-treated rats sho\\ ed s ign ificant ( p  < 0.005 ) 
i ncrease i n  p ia  rna cho lesterol leve l .  
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Figure ( 1 1 8 ) sho\\ s chole terol p lasma level  i n  GK rats treated with either ad i ponect in or 
v isfat i n .  e i ther drug has an) e ffect of plasma cho lesterol leve l .  
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F igure ( I  1 9 ) sho\\ s the pia rna level of trig lycerides in normal Wistar rat treated \\ ith 
e ither ad i ponect i n  or y i sfat in .  Wistar normal  rats treated \\ i th vi sfat in  ho\\ s ign i ficant (p < 
0.05 ) i ncrease i n  p ia  rna trig l y ceride leve l .  
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F igure ( 1 20 )  sho\\ the p ia ma l evel of trig l ) cerides in d iabet ic Wistar rats treated \\ ith 
e ither ad iponect i n  or vi fat in .  ate that d iabetic Wistar rats treated \\ i th ad iponect in ho\\ 
s ign i ficant ( p  < 0 .005 ) decrease i n  plasma triglycerides Ie e l .  
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F igure ( 1 2 1 )  ho\\ the p ia  ma level of triglycerides i n  GK rats treated \\ ith ei ther  
adi ponect in  or \ i sfat i n .  There i no s ign ificant d i fference bet"\veen the 3 groups al though 
there \\ as a trend to\\ ards a lo\\ er TG in treated rats .  
I X.3. P roteins  
Total prote i n  \\ a not mod i fled by the adm in istrat ion of e i ther adiponecti n or  v isfat i n  
except for G K  rats treated \\ i th  ad i ponecti n .  im i larly, p lasma amyla e was not ignificant l )  
al tered after the adm i n istrat ion of these drugs except for d iabet ic Wistar treated \\ ith v isfati n 
( F igure 1 22 - 1 24) .  
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Figure ( 1 22 )  ho\\ the p lasma lev e l  of total prote i n  in normal Wistar rats treated \\ i th 
e i ther ad i ponect i n  or  v i  fat in .  There \v a no s igni ficant d i fference between the 3 groups. 
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F igure ( 1 23 )  sho\\ s the p lasma level of total prote i n  in d iabet ic Wi  tar rats treated \\ i th 
e i ther ad i ponect i n  or v i sfat in .  There \\ as no s ignificant d i fference bet\\ een the 3 groups. 
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Figure ( 1 24 )  sho\\ s the p lasma level of total prote i n  in G K  rats treated w ith ei ther 
ad i ponect i n  or v i  Fat i n .  G K  rats treated with adi ponect in  sho\\ s igni ficant (p < 0.005 ) 
i nc rease i n  p ia  rna total prote i n  Ie e l .  
I XA. Kid n ey fu nct ion tests a nd electrolytes 
The p lasma level of creat i n i ne was not part icu lar!) altered after the admin i  trat ion of 
e ither adi ponect i n  or v i sfat i n  to e i ther  GK, normal or d iabetic Wistar rats. Hov, ever, the 
p lasma le\. e l  of b lood urea n i t rogen \\ as s igni ficantly reduced in normal Wistar rats treated 
\\ i th  e i ther adi ponect in  or isfat i n  and i n  GK rats treated \\ i th v i sfat i n  ( F igure 1 25 - 1 30) .  
P l asma sod i um \vas s ign i ficantl y  i nc reased i n  d iabetic Wistar rats treated \\ ith e i ther 
ad i ponect in  or i sfat i n  and in G K  rats treated v, ith adi ponect in but \\i as not al tered in  normal 
Wi star rats. The pattern of pia ma level of ch loride was im i lar to that of sod ium. The level 
of ch loride rose in tandem with that of sod ium in  d iabet ic Wistar rats treated \\ ith v isfat i n  
( F igure 1 3 1 - 1 36) .  The p lasma Ie e l  of phosphorus ro e in  d iabetic W i  tar rats treated \\ ith 
either ad i ponect in  or v isfat i n  and in GK rats treated \\ i th adi ponecti n ( F igures 1 37- 1 39) .  
Total 0 mola l it) was h igher i n  d iabet ic  W istar rats treated wi th  v isfat in  and GK rats treated 
\\ i th ad i ponect in .  0 other changes w ere observed ( F igures 1 40- 1 42) .  
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Figure ( 1 25 )  shows c reat i n i ne p ia ma le\ e l  in normal Wistar rats treated v" i th e i ther 
ad i ponect i n  or \. isfat in .  0 d i fference \v as obser\.ed in the three groups. 
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Figure ( 1 26 )  how s creat i n i ne plasma level i n  d iabetic Wistar rat treated \\ ith e i ther 
ad i ponect in  or  v isfat i n . 0 d ifference \\ as ob erved in the three group . 
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F!gur� ( 1 27 )  �ho\\ creat i n i ne p ia  rna level in G K  rats treated \\ ith either ad iponect in or 
\ I fat In. 0 d Ifference \\ a observed i n  the three groups. 
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Figure ( 1 28 )  sho\\ s the p Ia  rna level of B lood urea n i t rogen I in normal Wistar rat treated 
\\ i th e i ther ad i ponect i n  or v isfat in .  ote that ad i ponect in- and v isfati n-treated rat d isplayed 
ign i ficant ( p  < 0 .05 ) reduct ion in p lasma BU leve l .  
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Figure (1 29)  ho\\ s the p lasma Ie e l  of b lood urea n i t rogen i n  normal Wistar rats treated 
\\ i th e i ther ad i ponect in or \ i fat in .  0 s ign i ficant d i fference bet\\ een the three groups. 
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Figure ( 1 30 )  hovv s the b lood urea n i t rogen pia ma level in GK rats treated \\ ith e i ther 
adi ponect in  or v i sfat in .  Note that V isfat i n-treated rats disp la) ed signi ficant ( p  < 0.05 ) 
reduct ion i n  plasma B leve l .  
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Figure ( 1 3 1 )  sho\\ s p ia  ma ch loride p ia  ma le\ e l  i n  normal Wistar rat treated \\ ith e i ther 
ad i ponect i n  or \ i sfat i n .  0 d i fference \\ a ob er\ ed in the three groups. 
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Figure ( 1 32 )  sho\\ s p lasma Ie e l s  of ch loride in d iabet ic Wi tar rats treated with ei ther 
ad i ponect i n  or \ i sfati n .  ote that Wistar d iabet ic rats treated w i th v isfat in show sign i ficant 
(p <' 0.05 ) increase on Ch loride p lasma lev e l .  
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F igure ( 1 " 3 )  ho\\ s p lasma level  of ch loride i n  G K  rats treated with e i ther ad iponect in or 
\ i fat i n. 0 d ifference \\ as obse[\. ed i n  the three groups. 
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F igure ( 1 34 )  sho\\ s the level of p ia  ma sod ium ( a) in normal Wi tar rat treated \\ ith 
ei ther ad i ponect in or v isfat i n .  There w as no s ign i ficant d i fference bet\veen the 3 groups. 
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Figure ( 1 3 5 )  sho\\ the level of p lasma a)  in d iabetic Wistar rats treated w i th 
e i ther ad i ponecti n or \ i sfat i n .  ote that Wistar D iabet ic rats treated \\ i th Ad iponect in  or 
V i sfat i n  ho\\ ign i ficant ( p  < 0 .05)  increa e on sod i um plasma level 
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Figure ( 1 36 )  ho\\ the Ie el of p lasma sodi um ( a )  i n  OK rats treated \\ i th e i ther 
ad i ponect i n  or vi fat in .  ote that OK rats treated with ad iponect i n  sho\\ sign ificant 
(p < 0.05 ) i ncrease on plasma od ium leve . 1  
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F igure ( 1 37 )  ho\\ the effect of t reatment of normal Wi tar rat \\ ith adi ponecti n  or 
\ i  fat i n  on p ia  rna pho phoru Ie e l .  There is no s igni ficant d i fference bet\\ een the 3 
group . 
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Figure ( 1 3 8 )  shows the effect of treatment of d iabet ic Wistar rats \ i th ad iponect in  or 
\ i fati n  on p ia  rna phosphorus leve l .  ote that Wistar d iabet ic rats treated \\ ith e i ther 
adi ponect in  or \ i sfat i n  ho\\ igni ficant (p < 0 .005 ) i ncrease in plasma phosphorus leve\ .  
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the effect of treatment of G K  rat \v i th ad i ponect in  or \ isfat i n  on 
plasma phosphorus le\ e l .  ote that GK rats treated \\ i th  adiponect in  d isp layed sign ificant 
( p  < 0.005 ) i nc rea e in pia rna phosphorus leve l .  
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Figure ( 1 40 )  sho\\ p ia  rna osmola l i ty in normal W istar rats treated \v i th e i ther adi ponect in 
or v i  fat i n .  There \\  a no s igni  ficant d i  fference betw een the 3 groups. 
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F igure ( 1 -1- I )  ho\\ s p lasma 0 mola l it) i n  d iabetic W i  tar rats treated \v ith either ad iponect in 
or "\ i tat i n . ote that Wi tar D iabet ic rats treated w ith v isfat i n  hO\v s igni ficant ( p< 0.05 ) 
i nc rea e on osmola l  it) 
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F igure ( 1 -1-2 )  sho\\ p Ia  ma 0 molal ity 1 11 G K  rats treated \\ i th either ad iponect i n  or 
"\ i fat i n .  GK rats treated w ith ad i ponecti n  sho\\ s igni ficant ( p< 0.05 ) increa e on osmo lal it) 
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X. G e n e  e x p ress ion 
an)  gene inc lud ing. Hmox L H pa .. L and Pdx I \\ ere upregulated i n  GK rats treated 
\\ i th  both adi ponect in  and v i sfat i n .  In contrast. only isfat i n  \'v as able to increase the 
expr s ion of Gpx2 w h ich \\ a decrea ed in ad i ponect in-treated GK rat . G lucagon gene was 
marked l} reduced ( F i gure 1 43 ). 
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F igure ( 1 43 )  shO\\s re lat ive quanti ficat ion of gene express ion for GK rats treated \\ ith 
e i ther  ad i ponect in  or vi fat i n  
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The e. pre ion of Hspa4. Gpx2 and Pdx I \\ as marked l} e levated in  normal Wistar 
rat treated \\ i th ad i p  nect i n .  The expres ion of Pdx I and Gcg \\i a i ncreased in normal 
Wi  tar rat treated \\ i th \ isfat in  ( F igure 1 44 )  
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F igure ( 1 44 )  shO\v s rel at ive quant i ficat ion of gene express ion for normal Wi tar rats treated \\ ith 
e i ther  ad i ponect i n  or \ i sfat i n .  
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Pdx l gene i ncrea ed in  d iabet ic Wi tar rat treated \\ ith e i ther ad i ponect in on isfat in  
compared to contro l  ( F igure 1 45 ) .  
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Figure ( 1 45 )  hows re lat ive quanti ficat ion of gene express ion d iabet ic Wistar rats treated 
\\ i th  e i ther ad i ponect in  or v i sfat i n. 
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I. E ffect  of a d i po n ect in  a n d  v isfat in  on metabol ic  pa ra meters of 
a n i ma l  m od els  of d ia betes 
1 . 1 .  Body w e ight  
Bod) \ve ight gain i an important factor i n  the management of d iabetes. An ideal drug 
i n  the treatment of d iabete should decrease weight in obese patients and be neutral in lean 
patient . e i ther normal ,  d iabetic Wistar nor GK rats i ncreased wei oht s ion i ficant l v  after 0 0 . 
treatment \\ i th  e ither ad i ponect i n  or v isfat i n .  Ho\\ ever, a stead} body \\ eight gai n \\ a 
ob erv ed i n  al l an imals  i nvest igated. I t  i not c lear \\ h} these ad i poc) toki nes fa i led to 
Impro\ e weight .  Our results d id not corroborate those of (72 )  \\ ho reported that 
i ntracerebroventr icu lar do e of ad i ponect i n  reduced bod) weight. The} showed that the 
abi l i tJ of ad i ponect in  to i ncrease v .. eight was due to i ts abi l i ty to st imu late energy 
e'Xpend i ture .  
I though. the re lat ionsh ip  of v isfat i n  and body weight has been examined ( 73 ). the 
d i rect effect of thi ad i poc} tok i ne on bod) weight has not been in est igated . 
1 .2.  Blood gluco e 
Treatment of d iabel ic Wistar rat with ad iponect in  and v isfat in  i nduced s igni ficant 
decrease in b lood glucose level in \\ eek -+ of the experi ment. A s im i lar effect was ob erved i n  
G K  rat . Ho\\ e er. i n  d iabetic rats, the normal i zat ion of blood gluco e lev el was fol lo\\ ed bJ 
an increa e from \\ eeks 5- 8. The reason for thi fl uctuation i not c lear. It mal be due to 
o\; em hel m i ng of pancreat ic beta ce l l  b) free rad ical observed in d iabetes. The ob ervation 
on the effect of ad i ponect i n  on g l ucose loweri ng effect corroborates tho e of others ( 65 -66). 
The abi l i t) of  ad i ponect i n  to improve b lood gl ucose level may be due to the fact that 
adi ponect i n  is capable of st i mulat i ng energy expenditure ( 72) .  With regards io v isfat in ,  i t  has 
been reported that \; isfat i n  has an in u l i n-mimet ic action ( 82 ) .  
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1 .3 .  G l u co e tolerance te t 
Visfat i n  and adi ponect in-treated rats have better g l uco e hand l i ng 60 m in  after 
g luco e cha l lenge in normal W i  tar and GK rats. 0 s ign ificant improv ement in b lood 
gl ucose level \\ as ob erv ed a fter g luco e chal lenge i n  d iabet ic Wistar rats. The lack of effect 
of ad i ponect i n  and \ i fat in  in the d iabet i c  Wistar rats may be due to deranged ce l l u lar and 
biochem ical factor in d iabetic rat . It has been how n for example that calc ium i deranged 
i n  d iubete (67 ) .  i nce calc ium i a key factor in ce l l u lar transduction, the effect of these 
agents may fai l  to trigger the s ignal tran duction pathwa that re u l ts in insu l i n  secret ion 
from pancreat ic better ce l l s .  
I I . I m m u n o loca l izat ion of ad iponect in  a n d  visfat in in the 
p a n c reas 
d iponect i n  and v i sfat i n  \\ ere both located to  the is let of Langerhans i n  Wistar a 
\\ e l l  a G K  rats. Treatment of the ani mal models improves i let ce l l  morphology and s ize. 
Th i  how that ad i ponect in  may have t i  sue regenerat i v e  propert ies capable of i nduc ing a 
larger and more functional pancreat ic beta ce l l  mass. The large number of ad iponect in and 
v isfat i n  po i t ive cel l s  imp l ie a functiona l  ro le in the is let of Langerhan . The i r  presence in  
the  endocr ine pancreas a lso ind icated that they may i n fl uence the functions of other bioact ive 
agent i n  the is lets of Langerhans. 
I I I . I m m u n oloca l izat ion of ad iponect in  a n d  v isfat in  w i th 
p a n c reatic  h o r m o n es in the p a n c reas 
Ad iponect i n  co- local i zes \\  i th i n  u l in i n  the endocrine pancrea of Wi  tar and GK 
rat . The  number of  ad iponecti n-posit ive ce l ls decreased ign i ficantly after the onset of 
d iabetes. Th is  sho\.'\' s that ad iponect in  are i ndeed located in the pancreat ic beta cel l ,  \\ h ich are 
damaged a a resul t  of d iabetes. 
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I t  'v a i ntr igu ing to kno\, that orne ad i ponect in-conta in i ng ce l ls  a lso have e i ther insu l i n  or 
omato tat i n .  The ro le of  the dual  co-local ization is  unkno\v n. A lthough it  has been ho\\ n 
that the number  of ad i ponect i n  receptor i s  decreased in  pancreas of rats ( 74 ), it is c lear \\ h) 
ad i ponect i n  l i gand decreased \\ i th the onset of type d iabetes 
i m i larl) , isfat i n  also co-loca l ized \\l i th i nsul i n  in pancreat ic islets of GK,  normal 
and diabet ic Wi tar rats. This i nd icates that v i sfat i n  may p lay a role in  the regulation of beta 
cel l funct ion .  I n  fact a recent publ ication sho\'" that v i sfati n  can st imulate insu l i n  re lease 
from c lonal ce l l  l i ne (68 ) .  I n  add i t ion to the pre ence of \ isfat in  in pancreat ic is let cel ls, 
\ i rat i n  \\ a a lso observed in gl ucagon-secret i ng ce l l s .  I n  the same manner as for 
adi ponect in .  \ i fat i n  co- local ized 'v i th PP i n  the pancreas of Wistar rats treated \\ i th v isfati n .  
I I  of these observat ions support a ro le for ad i ponect in  and v isfat in  in  the metabol ism 
of pancreat ic hormone at the level of the endocrine pancreas 
I V. I m m u n o loca l izat ion  of ad iponect in  a n d  visfat in  i n  the fat 
tissu e  
[ n  order to veri fy pre\ lous reports that ad i ponect i n  and v isfat i n  are located to 
ad i pose t i ssue ( 82 ). we sta ined for these two ad i poc) tokines i n  subcutaneous as wel l as 
\ isceral fat t i ssues. These t\\ O adi pocytok ines are we l l  represented i n  both subcutaneous and 
v i scera l  fats. How ever. v isfat i n  appear to be more expressed in the epididy mal fat of G K  rat. 
recent report ( 7 5 )  howed that v isfat i n  expression is elevated in the omental fat of pregnant 
w oman. Th i  observ ation is s im i lar to ours i nce the metabol ism of g l ucose is deranged in the 
G K  rat as \\- e l l  as i n  many pregnancy albeit physio logical ly .  
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v. E ffect  of a d i po n ect in  and  visfat in  on pancreatic beta cel l  u ltra ­
stru ctu re 
Treatment of e i ther normal or d iabet ic Wistar or GK rats with ei ther adi ponect in  or 
\ i sfat i n  i mprov ed pancreat ic i s let ce l l  morpho logy. '\ i th i ncreased number of secretor� 
granule . The rea on for th i s  effect is not c lear. It is howev er, possib le that these 
ad i poC}10k ine ma� have prol i ferat i ve effect on the endocrine pancreas. orne tudies hav e 
con finned the protect i v e  effect of ad i ponect i n  on pancreat ic beta ce l l  l i ne ( 76) .  
VI. E ffect  of a d i ponectin a n d  v isfat in  on p lasma insu l i n  and  
gl u cagon level 
The p lasma Ie  e l s  of i nsu l i n  decreased s igni ficantly i n  normal Wistar and GK rats 
treated \\ i th \ i fat i n .  I n  contra t. the p lasma level of i n  u l i n  increased dramatical l) i n  
d iabet ic W i star rats t reated \\ i th v i sfati n .  The cause o f  the d i fference i s  not c lear. Howe er. i t  
i po ible that v isfat i n  i more effect ive when the need for insu l i n  i s  more evere. I n  
contra t. the p ia  rna level o f  d iabetic Wistar and G K  rats treated \'v i th ad i ponect in  i ncreased 
ign i ficant l )  at the end of the experi ment. The data obtai ned on i nsul i n  secretion agree' \\ i th 
that obtai ned on g lucagon.  because the plasma level of gl ucagon changed concurrentl) \\ ith 
that of p lasma in u l i n .  This observat ion corroborates that of (77 ). ,-\ ho sho\\ ed that 
adi ponecti n  can st imulate i n  v i vo as wel l  as in i tro i nsu l i n  release in nonnal m ice. I n  
add it ion.  v i sfat i n  has a lso been sho\\ n to  st imu late i nsul i n  re lease from pancreat ic ce l l  l i ne 
(68) .  The reason for the reduct ion i n  the level of insu l i n  released after treatment of normal 
Wistar and GK rats \'v i th v i sfati n is not c lear. 
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V I I .  I n  v i tro effect of a d i ponect in  and  v isfat in  on insu l i n  and  
g lucagon release fro m the  pancreas 
d i ponect in i nh i bi ted i n  u l i n  re lease from Wistar rats. I n  contrast, \ isfat i n  has no 
ign i ficant effect on i nsul i n  re lease from the i n  v i tro pancreas. The add i t ion of cho l i nergic 
and adrenergic antagon ists to ad iponect i n  i ncrea ed i nsul i n  release. 
[ n  contra 1. t he addi t ion of atrop ine and yohimb ine  i nh ibi ted \ i fat i n- i nduced response i n  GK 
rat . Th i  c learl ) ho\\ that ad i ponect in  and visfat in  act v ia  d i fferent signa l i ng path\\ a) s. 
d iponect in  has no effect on glucagon secret ion from the pancreas of GK rats but 
i nh ib i ted gl ucagon re lease from the pancreas of normal Wistar rat . Visfat in  also inh ib i t  
gl ucagon release at  one concentrat ion but  i nc rea ed g lucagon release at  the other. The reason 
for th is  phenomenon i not c lear. I t  i poss ib le that act ion of v i  fat i n  i b iphasic .  
The present observation contrad icts those of Okamoto et al 2008, and Bro\\ n et aL 2009 \\ ho 
reported that adi ponect i n  and vi rat i n  can st imulate insu l i n  re lease respect i \ e l] . 
V I I I . Effect of a d i po n ect in  a n d  visfat inon biochem ical  para meters 
VI I I . 1 .  L iver fu nct ion te ts 
Visfat i n  cau e s ign i ficant i ncreases in the albumin  level of d iabet ic Wi  tar rats '-' 
compared to adi ponect i n-treated and control W i  tar rats. [ n  contrast ad i ponect i n  i nduced 
large i nc rease i n  p lasma a l bum i n  Ie el in G K  rats compared to contro l .  The tv" o 
adi pocytok ines appear to fac i l i tate a lbum i n  product ion i n  d iabet ic models. 
The level of GGT was not al tered in GK and normal Wistar rats treated with e i ther 
ad i ponect i n  or v i sfat i n .  Parado. ical ly.  the p lasma lev e l  GGT of diabet ic \N i star rats treated 
adi ponect i n  i ncreased s ign i ficant ly .  The reason for th is  is not c lear. Ho\\ever. isfat i n  was 
able to ign i ficant l ]  reduce LDH level i n  d iabet ic W i star and GK rats. [t has been ho\v n that 
ad i ponect i n  can attenuate l i ver i nflammation ( 70) .  This m ight i mpl)  that ad iponect in  mal 
protect the l i ver from other nox ious factors. [ n  add it ion the two adipocytoki nes were able to 
reduce p lasma A L P  and A T level i n  normal Wistar and GK rats. 
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VI I I .2 .  Lipid 
I t  \\ a of i ntere t to  note that \ i sfati n i ncreased the plasma level of trig Jycerides i n  
normal W istar rat . d i ponect i n  d id  not s ign i ficant l y  affect tr iglyceride level i n  normal 
Wi tar rat . I n  add i t ion.  total cholestero l increased in normal Wistar rats treated \\ ith v isfat i n  
and i n  d iabet ic  Wistar treated \" i th e i ther ad i ponect i n  o r  v i sfat i n .  The cau e of  these 
di repanc ie  is unkno\\ n .  
VI I I .3. Prote ins  
Total prote i n  \\ as not mod i fied by the adm in i stration of ei ther ad iponect in or v i sfat i n  
except for G K  rats treated \\ i t h  ad i ponect in .  T h i  effect supports the protect ive role o f  
ad i ponect i n  i n  the l i \ er ( 70 ) .  
V I l l A. Kid ney fu nct ion tests a n d  electrolytes 
Al though the l evel  of creat i n i ne wa not al tered by ad i pocy tokine treatment, the plasma le\ e l  
of b lood urea n i trogen wa s ign ificantly reduced i n  normal Wistar rats treated \\ i th e i ther 
adi ponect i n  or v i sfat i n  and in GK rats treated \\ i th \ i sfat i n .  Many stud ies have show n that the 
le\ e l  of ad i ponect i n  i s  h igh i n  pat ient w i th renal fa i l ure ( 7 1 ) . How ever, it has been reported 
that very 10\\ i nstead of h igh plasma ad i ponect in  level  i s  recognized as a risk factor of 
card io\ascu lar morb id i ty and mortal i ty in pat ients suffering from chronic k idney fai l ure ( 78 ). 
P lasma sod ium w as s ign i ficant ly  i nc reased i n  d iabet ic  Wistar rats treated \\ i th e i ther 
ad i ponect i n  or  v i sfat i n  and in GK rats treated \\ i th ad i ponect i n  but \v as not altered in normal 
Wistar rats .  The pattern of p lasma level of ch loride \\ as s im i lar to that sod ium .  The le\ el of 
ch loride rose in tandem \\ i th that of sod ium in d iabet ic  Wi  tar rats treated \\ i th v i  fat i n .  
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The i nc rease i n  pia ma level of sod ium ma_ be due to the enhancement of i nsul i n  
becau e i n  u l i n  ha · been ho\\ n to cause sod ium retention. The p lasma level of  phosphorus 
ro e i n  d iabet ic \\. i star rat treated \\ ith e i ther ad i ponect i n  or v i sfat i n  and in GK rats treated 
\\ i th  adiponect i n .  Th is  ma) be due to a general improvement of the metabo l ic parameters. 
I X. Gene ex p ress ion  
Ad iponect in  and \ i sfat i n  increa e d  genes that are to protect pancreat ic is let cel l . These 
adi poc)tok. ines may be exert i ng the i r  effects v ia  these genes. The adm inistration of 
adi ponect i n  as \, e l l  as v i  fat i n  i nduced pdx I in both normal and d iabetic Wistar rats. The 
abi l i ty of these ad i pocytok ine to st imu late pdx 1 is  i ntr iguing because. pdx 1 has been show n 
to be im  0 1 \  ed i n  the development of the pancreas ( 79) .  The importance of ddx I in  pancreat ic 
de\ e lopment \\ as sho\\ n \\  hen transgenic mice became complete ly apancreat ic after 
tetracyc l i ne i nject ion the course of pregnancy (80) .  It does appears that ad i poc) tok ines such 
as \ isfat i n  can he lp  in the maintenance of pancreatic is let i ntegri ty v ia st imu lation of genes 
im oh ed in the de\ elopment and maturat ion of pancreat i c  beta cel l .  
Conclus ion  
Adiponect in  and v isfati n impro ed gl ucose to lerance i n  Wistar as \\ e l l  as GK rat . I n  
add i t ion.  the number and qual i ty of pancreat ic beta cel ls  impro ed after treatment \\ i th 
ad i ponect i n  and v i sfat i n  lead ing to increa e i n  the p lasma level of i nsul i n .  L iver and k idney 
parameter i nc l ud ing l act ic ac id dehydrogenase. a lka l i ne phosphatase. b lood urea n i trogen 
decreased s ign i ficant l )  after treatment \\ ith e i ther ad iponect i n  or v isfat in .  In conc l usion 
Ad iponect in  and v i sfat i n  amel iorate several metabol i c  parameters i n  animal mode ls of t) pe 1 
and ty pe 2 d iabetes. resu l t ing i n  improved glycemic contro l .  
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